positive	Chr.Start	Chr.End	Ref	Alt	Sitetype	chemicals	gene	type	level of evidence	phenotypes	Gene IDs	Gene Symbols	Location	VA count	CA count	Level 1/2 CA count	DG count	Haplotype	Synonyms	Variant ID	Gene Symbol	Label IDs	Label Names	PharmGKB Accession Id	Generic Names	Trade Names	Brand Mixtures	Cross-references	Dosing Guideline	Dosing Guideline Sources	Top FDA Label Testing Level	Top Any Drug Label Testing Level	Source ID
1;2	chr10:96741053	chr10:96741053	A	C	CYP2C9*3	iosartan	CYP2C9	Efficacy	3	.	PA126	CYP2C9	[GRCh37]chr10:96741053	98	11	4	0	Yes	XP_005269632.1:p.Ile359Leu, rs61212474, XP_005269632.1:p.Ile359=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NM_000771.3:c.1075A=, NP_000762.2:p.Ile359=, [GRCh37]chr10:96741053, rs1057910, rs3198471, NC_000010.11:g.94981296A=, NC_000010.10:g.96741053A>C, XM_005269575.1:c.1075A>C, [GRCh38]chr10:94981296, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, NG_008385.1:g.47639A>C, rs17847042, NP_000762.2:p.I359L, NC_000010.10:g.96741053A=, NM_000771.3:c.1075A>C	PA166153959	CYP2C9	PA166122826;PA166104843;PA166153432;PA166104922;PA166160007;PA166163422;PA166104860;PA166105222;PA166104917;PA166104776;PA166127647;PA166127732;PA166160153	Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for celecoxib and CYP2C9;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for flurbiprofen and CYP2C9;Annotation of FDA Label for lesinurad and CYP2C9;Annotation of FDA Label for marinol and CYP2C9;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for piroxicam and CYP2C9;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1;Annotation of HCSC Label for celecoxib and CYP2C9;Annotation of HCSC Label for warfarin and CYP2C9,VKORC1;Annotation of PMDA Label for celecoxib and CYP2C9	PA450268	losartan potassium	Cozaar,"DUP 89","Hyzaar","Lacidipine","Lortaan"	.	Web Resource:http://en.wikipedia.org/wiki/Losartan,"National Drug Code Directory:0006-0951-54","DrugBank:DB00678","ChEBI:6541","KEGG Compound:C07072","PubChem Compound:3961","PubChem Substance:205151","PubChem Substance:46506538","IUPHAR Ligand:590","Drugs Product Database (DPD):02182882","ChemSpider:3824","Therapeutic Targets Database:DAP000523","FDA Drug Label at DailyMed:5ac32c20-169d-475a-fc8a-934f758d6ab0","ClinicalTrials.gov:NCT00617877","ClinicalTrials.gov:NCT00683124","ClinicalTrials.gov:NCT00732966"	No	.	.	.	18971529;14504849;19604036
1;2	chr10:115805056	chr10:115805056	G	C	ADRB1 rs1801253	metoprolol	ADRB1	Efficacy	3	Hypertension	PA38	ADRB1	[GRCh37]chr10:115805056	39	6	0	0	Yes	rs28365052, NM_000684.2:c.1165G>C, NG_012187.1:g.6251G>C, NC_000010.11:g.114045297G>C, rs17091259, rs59130083, rs12718339, NC_000010.10:g.115805056G>C, NP_000675.1:p.Gly389Arg, rs1801253, NP_000675.1:p.G389R, [GRCh37]chr10:115805056, [GRCh38]chr10:114045297	PA166153977	.	.	.	PA450480	Metoprolol Tartrate,"Metoprolol succinate"	Beloc,"Betaloc","Lopresor","Lopresoretic","Lopressor","Lopressor HCT","Metroprolol","Prelis","Selo-Zok","Seloken","Selopral","Toprol","Toprol XL","Toprol-XL"	.	Web Resource:http://en.wikipedia.org/wiki/Metoprolol,"National Drug Code Directory:58177-293-04","DrugBank:DB00264","ChEBI:6904","KEGG Compound:C07202","KEGG Drug:D02358","PubChem Compound:4171","PubChem Substance:205122","PubChem Substance:46506211","IUPHAR Ligand:553","Drugs Product Database (DPD):02253518","BindingDB:25756","ChemSpider:4027","Therapeutic Targets Database:DAP000481","FDA Drug Label at DailyMed:a8374722-d2b5-4eb3-bbcd-6ddc52e763ba","ClinicalTrials.gov:NCT00246519","ClinicalTrials.gov:NCT01203852","ClinicalTrials.gov:NCT01970501"	No	DPWG	Informative PGx	Actionable PGx	20643254;29095089
1;2	chr12:112241766	chr12:112241766	G	A	ALDH2*2	nitroglycerin	ALDH2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16051882;18787169
1;2	chr12:21331549	chr12:21331549	T	C	SLCO1B1 rs4149056	cerivastatin	SLCO1B1	Toxicity/ADR	2A	Rhabdomyolysis	PA134865839	SLCO1B1	[GRCh37]chr12:21331549	113	23	5	0	Yes	[GRCh38]chr12:21178615, NC_000012.12:g.21178615T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, NC_000012.11:g.21331549T>C, rs4149056, rs52816141, [GRCh37]chr12:21331549, NP_006437.3:p.V174A, rs60037639, NG_011745.1:g.52422T>C	PA166154579	SLCO1B1	PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	PA448897	Cerivastatin sodium,"Cerivastatin, sodium salt"	Baycol,"Lipobay","Rivastatin"	.	Web Resource:http://en.wikipedia.org/wiki/Cerivastatin,"DrugBank:DB00439","PDB:116","Chemical Abstracts Service:143201-11-0","ChEBI:3558","KEGG Compound:C07966","PubChem Compound:446156","PubChem Substance:206660","PubChem Substance:46505877","Drugs Product Database (DPD):02237325","BindingDB:18376","ChemSpider:393588"	No	.	.	.	15970799
1;2	chr12:21331549	chr12:21331549	T	C	SLCO1B1 rs4149056	simvastatin	SLCO1B1	Toxicity/ADR	1A	Muscular Diseases,Myopathy, Central Core	PA134865839	SLCO1B1	[GRCh37]chr12:21331549	113	23	5	0	Yes	[GRCh38]chr12:21178615, NC_000012.12:g.21178615T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, NC_000012.11:g.21331549T>C, rs4149056, rs52816141, [GRCh37]chr12:21331549, NP_006437.3:p.V174A, rs60037639, NG_011745.1:g.52422T>C	PA166154579	SLCO1B1	PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	PA451363	Simvastatin [Usan:Ban:Inn],"Simvastatina [Spanish]","Simvastatine [French]","Simvastatinum [Latin]"	Cholestat,"Coledis","Colemin","Corolin","Denan","Labistatin","Lipex","Lodales","Medipo","Nivelipol","Pantok","Rendapid","Simovil","Sinvacor","Sivastin","Synvinolin","Vasotenal","Vytorin","Zocor","Zocord"	Inegy (Simvastatin + Ezetimibe)	Web Resource:http://en.wikipedia.org/wiki/Simvastatin,"National Drug Code Directory:16714-681-01","DrugBank:DB00641","PDB:SIM","Chemical Abstracts Service:79902-63-9","ChEBI:9150","KEGG Drug:D00434","PubChem Compound:54454","PubChem Substance:7847500","Drugs Product Database (DPD):02253747","HET:SIM","Therapeutic Targets Database:DAP001519","FDA Drug Label at DailyMed:0376351b-f1a0-43e5-a0b4-533072c49f39","ClinicalTrials.gov:NCT00451828","ClinicalTrials.gov:NCT00452244","ClinicalTrials.gov:NCT00807950","ClinicalTrials.gov:NCT01061671","ClinicalTrials.gov:NCT01156545"	Yes	CPIC	.	.	28812116;24263182
1;2	chr12:21331549	chr12:21331549	T	C	SLCO1B1 rs4149056	atorvastatin	SLCO1B1	Toxicity/ADR,Metabolism/PK	3	.	PA134865839	SLCO1B1	[GRCh37]chr12:21331549	113	23	5	0	Yes	[GRCh38]chr12:21178615, NC_000012.12:g.21178615T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, NC_000012.11:g.21331549T>C, rs4149056, rs52816141, [GRCh37]chr12:21331549, NP_006437.3:p.V174A, rs60037639, NG_011745.1:g.52422T>C	PA166154579	SLCO1B1	PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	PA448500	Atorvastatin calcium	Atogal,"Atorpic","Cardyl","Faboxim","Hipolixan","Lipitor","Lipotropic","Lipovastatinklonal","Liprimar","Lowden","Normalip","Sincol","Sortis","Sotis","Torvacard","Torvast","Totalip","Tozalip","Tulip","Vastina","Xanator","Xarator","Xavator","Zurinel"	.	Web Resource:http://en.wikipedia.org/wiki/Atorvastatin,"National Drug Code Directory:0071-0155-23","DrugBank:DB01076","PDB:117","ChEBI:2910","KEGG Compound:C06834","PubChem Compound:60823","PubChem Substance:205162","PubChem Substance:46506188","Drugs Product Database (DPD):02243097","BindingDB:22164","ChemSpider:54810","HET:117","Therapeutic Targets Database:DAP000553","FDA Drug Label at DailyMed:c6e131fe-e7df-4876-83f7-9156fc4e8228","ClinicalTrials.gov:NCT00361283","ClinicalTrials.gov:NCT01112670"	No	.	Informative PGx	Informative PGx	19374892;28812116;24263182
1;2	chr12:21331549	chr12:21331549	T	C	SLCO1B1 5rs4149056	pitavastatin	SLCO1B1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	17460607;16198653;18408565
1;2	chr10:96741053	chr10:96741053	A	C	CYP2C9*3	warfarin	CYP2C9	Dosage	1A	.	PA126	CYP2C9	[GRCh37]chr10:96741053	98	11	4	0	Yes	XP_005269632.1:p.Ile359Leu, rs61212474, XP_005269632.1:p.Ile359=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NM_000771.3:c.1075A=, NP_000762.2:p.Ile359=, [GRCh37]chr10:96741053, rs1057910, rs3198471, NC_000010.11:g.94981296A=, NC_000010.10:g.96741053A>C, XM_005269575.1:c.1075A>C, [GRCh38]chr10:94981296, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, NG_008385.1:g.47639A>C, rs17847042, NP_000762.2:p.I359L, NC_000010.10:g.96741053A=, NM_000771.3:c.1075A>C	PA166153959	CYP2C9	PA166122826;PA166104843;PA166153432;PA166104922;PA166160007;PA166163422;PA166104860;PA166105222;PA166104917;PA166104776;PA166127647;PA166127732;PA166160153	Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for celecoxib and CYP2C9;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for flurbiprofen and CYP2C9;Annotation of FDA Label for lesinurad and CYP2C9;Annotation of FDA Label for marinol and CYP2C9;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for piroxicam and CYP2C9;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1;Annotation of HCSC Label for celecoxib and CYP2C9;Annotation of HCSC Label for warfarin and CYP2C9,VKORC1;Annotation of PMDA Label for celecoxib and CYP2C9	PA451906	Warfarin sodium	Athrombin,"Athrombin-K","Athrombine-K","Brumolin","Co-Rax","Coumadin","Coumadin Tabs","Coumafen","Coumafene","Coumaphen","Coumaphene","Coumarins","Coumefene","D-Con","Dethmor","Dethnel","Dicusat E","Frass-Ratron","Jantoven","Kumader","Kumadu","Kumatox","Kypfarin","Latka 42","Mar-Frin","Marevan","Maveran","Panwarfin","Place-Pax","Prothromadin","RAX","Rosex","Sofarin","Solfarin","Sorexa Plus","Temus W","Tintorane","Tox-Hid","Vampirinip II","Vampirinip III","Waran","Warf 42","Warfarat","Warfarin Plus","Warfarin Q","Warfarine","Warficide","Warfilone","Zoocoumarin"	.	Web Resource:http://en.wikipedia.org/wiki/Warfarin,"National Drug Code Directory:0056-0169-70","DrugBank:DB00682","Chemical Abstracts Service:129-06-6","ChEBI:10033","KEGG Compound:C01541","PubChem Compound:6691","PubChem Substance:4702","Drugs Product Database (DPD):02244463","BindingDB:50088240","Therapeutic Targets Database:DAP000770","FDA Drug Label at DailyMed:d91934a0-902e-c26c-23ca-d5accc4151b6","ClinicalTrials.gov:NCT00247702","ClinicalTrials.gov:NCT00334464","ClinicalTrials.gov:NCT00377143","ClinicalTrials.gov:NCT00511173","ClinicalTrials.gov:NCT00603317","ClinicalTrials.gov:NCT00634907","ClinicalTrials.gov:NCT00654823","ClinicalTrials.gov:NCT00700895","ClinicalTrials.gov:NCT00830570","ClinicalTrials.gov:NCT00904293","ClinicalTrials.gov:NCT00927862","ClinicalTrials.gov:NCT00970892","ClinicalTrials.gov:NCT00993200","ClinicalTrials.gov:NCT01006733","ClinicalTrials.gov:NCT01119300","ClinicalTrials.gov:NCT01178034","ClinicalTrials.gov:NCT01305148","ClinicalTrials.gov:NCT01447511","ClinicalTrials.gov:NCT01520402","ClinicalTrials.gov:NCT01610141","ClinicalTrials.gov:NCT01633957","ClinicalTrials.gov:NCT01855737"	Yes	CPIC,"CPNDS"	Actionable PGx	Actionable PGx	21782804;9352571;25246753
2	chr19:15990431	chr19:15990431	C	T	CYP4F2*3	warfarin	CYP4F2	Dosage	1B	Hemorrhage,Intracranial Hemorrhages,Myocardial Infarction,Peripheral Vascular Diseases,Thromboembolism,venous thromboembolism	PA27121	CYP4F2	[GRCh37]chr19:15990431	115	6	3	0	Yes	[GRCh37]chr19:15990431, NP_001073.3:p.Val433Met, NC_000019.9:g.15990431C>T, rs116975254, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, rs52819608, rs57319528, NP_001073.3:p.V433M, rs2108622, NC_000019.10:g.15879621C>T, [GRCh38]chr19:15879621	PA166155381	.	.	.	PA451906	Warfarin sodium	Athrombin,"Athrombin-K","Athrombine-K","Brumolin","Co-Rax","Coumadin","Coumadin Tabs","Coumafen","Coumafene","Coumaphen","Coumaphene","Coumarins","Coumefene","D-Con","Dethmor","Dethnel","Dicusat E","Frass-Ratron","Jantoven","Kumader","Kumadu","Kumatox","Kypfarin","Latka 42","Mar-Frin","Marevan","Maveran","Panwarfin","Place-Pax","Prothromadin","RAX","Rosex","Sofarin","Solfarin","Sorexa Plus","Temus W","Tintorane","Tox-Hid","Vampirinip II","Vampirinip III","Waran","Warf 42","Warfarat","Warfarin Plus","Warfarin Q","Warfarine","Warficide","Warfilone","Zoocoumarin"	.	Web Resource:http://en.wikipedia.org/wiki/Warfarin,"National Drug Code Directory:0056-0169-70","DrugBank:DB00682","Chemical Abstracts Service:129-06-6","ChEBI:10033","KEGG Compound:C01541","PubChem Compound:6691","PubChem Substance:4702","Drugs Product Database (DPD):02244463","BindingDB:50088240","Therapeutic Targets Database:DAP000770","FDA Drug Label at DailyMed:d91934a0-902e-c26c-23ca-d5accc4151b6","ClinicalTrials.gov:NCT00247702","ClinicalTrials.gov:NCT00334464","ClinicalTrials.gov:NCT00377143","ClinicalTrials.gov:NCT00511173","ClinicalTrials.gov:NCT00603317","ClinicalTrials.gov:NCT00634907","ClinicalTrials.gov:NCT00654823","ClinicalTrials.gov:NCT00700895","ClinicalTrials.gov:NCT00830570","ClinicalTrials.gov:NCT00904293","ClinicalTrials.gov:NCT00927862","ClinicalTrials.gov:NCT00970892","ClinicalTrials.gov:NCT00993200","ClinicalTrials.gov:NCT01006733","ClinicalTrials.gov:NCT01119300","ClinicalTrials.gov:NCT01178034","ClinicalTrials.gov:NCT01305148","ClinicalTrials.gov:NCT01447511","ClinicalTrials.gov:NCT01520402","ClinicalTrials.gov:NCT01610141","ClinicalTrials.gov:NCT01633957","ClinicalTrials.gov:NCT01855737"	Yes	CPIC,"CPNDS"	Actionable PGx	Actionable PGx	21084764;19297519;23132553
1;2	chr16:31107689	chr16:31107689	C	T	VKORC1 rs9923231	warfarin	VKORC1	Dosage	1A	.	PA134899581,PA165450635,PA133787052	BCKDK,PRSS53,VKORC1	[GRCh37]chr16:31107689	209	5	4	0	Yes	NC_000016.10:g.31096368C>T, rs60511154, NC_000016.10:g.31096368C=, NM_024006.5:c.-1639G=, NC_000016.9:g.31107689C>T, XR_950848.1:n.-31G=, rs117572127, NM_001311311.1:c.-1639G=, NM_206824.2:c.-1639G=, XM_011545945.1:c.-1252G>A, NM_001311311.1:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_011545944.1:c.-1252G>A, NM_024006.5:c.-1639G>A, XM_005255568.1:c.-1639G>A, NG_011564.1:g.3588G=, XM_011545943.1:c.-1639G>A, rs17878363, rs9923231, NC_000016.9:g.31107689C=, XM_011545945.1:c.-1252G=, [GRCh38]chr16:31096368, NG_011564.1:g.3588G>A, XR_243303.1:n.-990G=, XM_011545943.1:c.-1639G=, [GRCh37.p13]chr16:31107689, NM_206824.2:c.-1639G>A, XR_243303.1:n.-990G>A, XM_011545944.1:c.-1252G=, XR_950848.1:n.-31G>A	PA166155091	.	.	.	PA451906	Warfarin sodium	Athrombin,"Athrombin-K","Athrombine-K","Brumolin","Co-Rax","Coumadin","Coumadin Tabs","Coumafen","Coumafene","Coumaphen","Coumaphene","Coumarins","Coumefene","D-Con","Dethmor","Dethnel","Dicusat E","Frass-Ratron","Jantoven","Kumader","Kumadu","Kumatox","Kypfarin","Latka 42","Mar-Frin","Marevan","Maveran","Panwarfin","Place-Pax","Prothromadin","RAX","Rosex","Sofarin","Solfarin","Sorexa Plus","Temus W","Tintorane","Tox-Hid","Vampirinip II","Vampirinip III","Waran","Warf 42","Warfarat","Warfarin Plus","Warfarin Q","Warfarine","Warficide","Warfilone","Zoocoumarin"	.	Web Resource:http://en.wikipedia.org/wiki/Warfarin,"National Drug Code Directory:0056-0169-70","DrugBank:DB00682","Chemical Abstracts Service:129-06-6","ChEBI:10033","KEGG Compound:C01541","PubChem Compound:6691","PubChem Substance:4702","Drugs Product Database (DPD):02244463","BindingDB:50088240","Therapeutic Targets Database:DAP000770","FDA Drug Label at DailyMed:d91934a0-902e-c26c-23ca-d5accc4151b6","ClinicalTrials.gov:NCT00247702","ClinicalTrials.gov:NCT00334464","ClinicalTrials.gov:NCT00377143","ClinicalTrials.gov:NCT00511173","ClinicalTrials.gov:NCT00603317","ClinicalTrials.gov:NCT00634907","ClinicalTrials.gov:NCT00654823","ClinicalTrials.gov:NCT00700895","ClinicalTrials.gov:NCT00830570","ClinicalTrials.gov:NCT00904293","ClinicalTrials.gov:NCT00927862","ClinicalTrials.gov:NCT00970892","ClinicalTrials.gov:NCT00993200","ClinicalTrials.gov:NCT01006733","ClinicalTrials.gov:NCT01119300","ClinicalTrials.gov:NCT01178034","ClinicalTrials.gov:NCT01305148","ClinicalTrials.gov:NCT01447511","ClinicalTrials.gov:NCT01520402","ClinicalTrials.gov:NCT01610141","ClinicalTrials.gov:NCT01633957","ClinicalTrials.gov:NCT01855737"	Yes	CPIC,"CPNDS"	Actionable PGx	Actionable PGx	21747589;19135231;22040439
1;2	chr10:96541616	chr10:96541616	G	A	CYP2C19*2	clopidogrel	CYP2C19	Efficacy,Toxicity/ADR	1A	Acute coronary syndrome,Cardiovascular Diseases,Thrombosis	PA124	CYP2C19	[GRCh37]chr10:96541616	133	11	4	0	Yes	NP_000760.1:p.Pro227=, NM_000769.2:c.681G>A, rs116940633, [GRCh37]chr10:96541616, NG_008384.2:g.24154G>A, [GRCh38]chr10:94781859, rs17879456, rs60361278, NC_000010.11:g.94781859G>A, NP_000760.1:p.P227P, rs4244285, NC_000010.10:g.96541616G>A, NM_000769.1:c.681G>A	PA166154053	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	PA449053	.	Clopidogrel [Ban:Inn],"Clopidogrel sulfate","Plavix"	.	Web Resource:http://en.wikipedia.org/wiki/Clopidogrel,"National Drug Code Directory:63653-1171-6","DrugBank:DB00758","Chemical Abstracts Service:120202-66-6","ChEBI:37941","KEGG Drug:D00769","PubChem Compound:60606","PubChem Substance:196885","PubChem Substance:46507295","Drugs Product Database (DPD):02238682","ChemSpider:54632","Therapeutic Targets Database:DAP000178","FDA Drug Label at DailyMed:01b14603-8f29-4fa3-8d7e-9d523f802e0b","ClinicalTrials.gov:NCT00413608","ClinicalTrials.gov:NCT00799396","ClinicalTrials.gov:NCT01039480","ClinicalTrials.gov:NCT01097343","ClinicalTrials.gov:NCT01184300","ClinicalTrials.gov:NCT01341600","ClinicalTrials.gov:NCT01452139","ClinicalTrials.gov:NCT01452152","ClinicalTrials.gov:NCT01495845","ClinicalTrials.gov:NCT01503658","ClinicalTrials.gov:NCT01611545","ClinicalTrials.gov:NCT01815008","ClinicalTrials.gov:NCT01968499","ClinicalTrials.gov:NCT01990989"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	20833683;22757746;22228204
1;2	chr10:96540410	chr10:96540410	G	A	CYP2C19*3	clopidogrel	CYP2C19	Efficacy,Toxicity/ADR	1A	Acute coronary syndrome,Coronary Artery Disease	PA124	CYP2C19	[GRCh37]chr10:96540410	32	3	1	0	Yes	[GRCh37]chr10:96540410, NG_008384.2:g.22948G>A, rs52827375, rs57081121, rs4986893, NC_000010.10:g.96540410G>A, [GRCh38]chr10:94780653, NM_000769.2:c.636G>A, NC_000010.11:g.94780653G>A, NP_000760.1:p.Trp212Ter, NP_000760.1:p.W212*	PA166154070	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	PA449053	.	Clopidogrel [Ban:Inn],"Clopidogrel sulfate","Plavix"	.	Web Resource:http://en.wikipedia.org/wiki/Clopidogrel,"National Drug Code Directory:63653-1171-6","DrugBank:DB00758","Chemical Abstracts Service:120202-66-6","ChEBI:37941","KEGG Drug:D00769","PubChem Compound:60606","PubChem Substance:196885","PubChem Substance:46507295","Drugs Product Database (DPD):02238682","ChemSpider:54632","Therapeutic Targets Database:DAP000178","FDA Drug Label at DailyMed:01b14603-8f29-4fa3-8d7e-9d523f802e0b","ClinicalTrials.gov:NCT00413608","ClinicalTrials.gov:NCT00799396","ClinicalTrials.gov:NCT01039480","ClinicalTrials.gov:NCT01097343","ClinicalTrials.gov:NCT01184300","ClinicalTrials.gov:NCT01341600","ClinicalTrials.gov:NCT01452139","ClinicalTrials.gov:NCT01452152","ClinicalTrials.gov:NCT01495845","ClinicalTrials.gov:NCT01503658","ClinicalTrials.gov:NCT01611545","ClinicalTrials.gov:NCT01815008","ClinicalTrials.gov:NCT01968499","ClinicalTrials.gov:NCT01990989"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	23429358;22045970;27653892
1;2	chr19:15990431	chr19:15990431	C	T	CYP4F2*3	acenocoumarol	CYP4F2	Dosage	2A	Atrial Fibrillation	PA27121	CYP4F2	[GRCh37]chr19:15990431	115	6	3	0	Yes	[GRCh37]chr19:15990431, NP_001073.3:p.Val433Met, NC_000019.9:g.15990431C>T, rs116975254, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, rs52819608, rs57319528, NP_001073.3:p.V433M, rs2108622, NC_000019.10:g.15879621C>T, [GRCh38]chr19:15879621	PA166155381	.	.	.	PA452632	Acenocoumarin,"Acenocoumarolum [inn-latin]","Nicoumalone","Nicumalon","Nitrophenylacetylethyl-4-hydroxycoumarine","Nitrovarfarian","Nitrowarfarin"	Ascumar,"Mini-sintrom","Neositron","Sincoumar","Sinkumar","Sinthrom","Sinthrome","Sintrom","Syncoumar","Syncumar","Syntrom","Zotil"	.	Web Resource:http://en.wikipedia.org/wiki/Acenocoumarol,"DrugBank:DB01418","Chemical Abstracts Service:152-72-7","ChEBI:53766","KEGG Drug:D07064","PubChem Compound:9052","PubChem Substance:10321722","Drugs Product Database (DPD):00010383","Therapeutic Targets Database:DAP000772","ClinicalTrials.gov:NCT01119261","ClinicalTrials.gov:NCT01492777"	No	DPWG	.	.	19270263;23132553
1;2	chr1:20915701	chr1:20915701	A	C	CDA rs2072671	gemcitabine	CDA	Toxicity/ADR	3	Carcinoma, Non-Small-Cell Lung,Mesothelioma,Pancreatic Neoplasms	PA98	CDA	[GRCh37]chr1:20915701	32	3	0	0	Yes	[GRCh38]chr1:20589208, NM_001785.2:c.79A>C, rs2072671, NP_001776.1:p.Lys27Gln, NC_000001.10:g.20915701A>C, rs57221291, NC_000001.11:g.20589208A>C, [GRCh37]chr1:20915701, NP_001776.1:p.K27Q	PA166153667	.	.	.	PA449748	.	DDFC,"DFDC","GEO","Gemcin","Gemcitabina [INN-Spanish]","Gemcitabine HCl","Gemcitabine hydrochloride","Gemcitabinum [INN-Latin]","Gemtro","Gemzar"	.	Web Resource:http://en.wikipedia.org/wiki/Gemcitabine,"National Drug Code Directory:0002-7501-01","DrugBank:DB00441","PDB:GEO","Chemical Abstracts Service:122111-03-9","ChEBI:175901","KEGG Compound:C07650","KEGG Drug:D02368","PubChem Compound:60750","PubChem Substance:46506425","PubChem Substance:9852","Drugs Product Database (DPD):02230309","ChemSpider:54753","HET:GEO","Therapeutic Targets Database:DAP001246","FDA Drug Label at DailyMed:9dc35c59-f4f3-43b4-8251-0cf5c06cdc80","ClinicalTrials.gov:NCT00088894","ClinicalTrials.gov:NCT00128856","ClinicalTrials.gov:NCT00212069","ClinicalTrials.gov:NCT00226577","ClinicalTrials.gov:NCT00235235","ClinicalTrials.gov:NCT00556023","ClinicalTrials.gov:NCT00601159","ClinicalTrials.gov:NCT00617656","ClinicalTrials.gov:NCT00620295","ClinicalTrials.gov:NCT00660426","ClinicalTrials.gov:NCT00695994","ClinicalTrials.gov:NCT00705549","ClinicalTrials.gov:NCT00792701","ClinicalTrials.gov:NCT00951444","ClinicalTrials.gov:NCT00981162","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01063192","ClinicalTrials.gov:NCT01068327","ClinicalTrials.gov:NCT01121406","ClinicalTrials.gov:NCT01213381","ClinicalTrials.gov:NCT01416662","ClinicalTrials.gov:NCT01652794","ClinicalTrials.gov:NCT01714037","ClinicalTrials.gov:NCT01867892","ClinicalTrials.gov:NCT01951157","ClinicalTrials.gov:NCT01970553"	No	.	.	.	22546611;18347182
1;2	chr1:97915614	chr1:97915614	C	T	DPYD*2A	capecitabine	DPYD	Toxicity/ADR,Metabolism/PK	1A	Neoplasms	PA145	DPYD	[GRCh37]chr1:97915614	54	2	1	0	Yes	NC_000001.11:g.97450058C>T, NM_000110.3:c.1905+1G>A, XM_005270561.1:c.1794+1G>A, NG_008807.2:g.476002G>A, NC_000001.10:g.97915614C>T, [GRCh37]chr1:97915614, [GRCh38]chr1:97450058, XM_005270562.3:c.1689+1G>A, rs3918290, rs199469548, XM_005270563.1:c.1905+1G>A, XM_005270562.1:c.1689+1G>A, XM_006710397.2:c.1905+1G>A, rs386589337	PA166153760	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	.	.	.	.	.	.	.	.	.	20507294;26573078;23930673
1;2	chr6:18143955	chr6:18143955	C	G	TPMT*2	mercaptopurine	TPMT	Dosage,Toxicity/ADR	1A	.	.	.	.	.	.	.	.	.	.	.	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	.	.	.	.	.	.	.	.	.	22304581;18708949
1;2	chr6:18139228	chr6:18139228	C	T	TPMT*3A	mercaptopurine	TPMT	Dosage,Toxicity/ADR	1A	.	.	.	.	.	.	.	.	.	.	.	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	.	.	.	.	.	.	.	.	.	17885628
1;2	chr6:18130918	chr6:18130918	T	C	TPMT*3A	mercaptopurine	TPMT	Dosage,Toxicity/ADR	3	Precursor Cell Lymphoblastic Leukemia-Lymphoma	PA356	TPMT	[GRCh37]chr6:18130918	18	3	0	0	Yes	NC_000006.12:g.18130687T>C, XP_011513141.1:p.Tyr225Cys, rs61510596, [GRCh37]chr6:18130918, XP_011513142.1:p.Tyr217Cys, rs16880254, NP_000358.1:p.Y240C, rs1801205, XM_011514839.1:c.674A>G, NC_000006.11:g.18130918T>C, rs52798150, rs1142345, rs29001646, NG_012137.2:g.29457A>G, NM_000367.3:c.719A>G, XM_011514840.1:c.650A>G, [GRCh38]chr6:18130687, NP_000358.1:p.Tyr240Cys	PA166156978	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA450379	6 MP,"6-Mercaptopurine","MP","Mercaptopurine Monohydrate","Mercapurin"	Ismipur,"Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mern","Puri-Nethol","Purimethol","Purinethol","Xaluprine"	.	Web Resource:http://en.wikipedia.org/wiki/Mercaptopurine,"National Drug Code Directory:0378-3547-52","DrugBank:DB01033","ChEBI:2208","KEGG Compound:C02380","KEGG Drug:D04931","PubChem Compound:667490","PubChem Substance:46506988","PubChem Substance:5422","Drugs Product Database (DPD):00004723","BindingDB:50200098","ChemSpider:580869","Therapeutic Targets Database:DAP000147","FDA Drug Label at DailyMed:15904472-4c32-4224-95d3-eb131a7ff9c8","ClinicalTrials.gov:NCT00521950","ClinicalTrials.gov:NCT00549848"	Yes	CPIC,"DPWG"	Testing recommended	Testing recommended	17885628
1;2	chr6:18139228	chr6:18139228	C	T	TPMT*3B	mercaptopurine	TPMT	Dosage,Toxicity/ADR	1A	.	.	.	.	.	.	.	.	.	.	.	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	.	.	.	.	.	.	.	.	.	16202677;18987660
1;2	chr6:18130918	chr6:18130918	T	C	TPMT*3C	mercaptopurine	TPMT	Dosage,Toxicity/ADR	3	Precursor Cell Lymphoblastic Leukemia-Lymphoma	PA356	TPMT	[GRCh37]chr6:18130918	18	3	0	0	Yes	NC_000006.12:g.18130687T>C, XP_011513141.1:p.Tyr225Cys, rs61510596, [GRCh37]chr6:18130918, XP_011513142.1:p.Tyr217Cys, rs16880254, NP_000358.1:p.Y240C, rs1801205, XM_011514839.1:c.674A>G, NC_000006.11:g.18130918T>C, rs52798150, rs1142345, rs29001646, NG_012137.2:g.29457A>G, NM_000367.3:c.719A>G, XM_011514840.1:c.650A>G, [GRCh38]chr6:18130687, NP_000358.1:p.Tyr240Cys	PA166156978	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA450379	6 MP,"6-Mercaptopurine","MP","Mercaptopurine Monohydrate","Mercapurin"	Ismipur,"Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mern","Puri-Nethol","Purimethol","Purinethol","Xaluprine"	.	Web Resource:http://en.wikipedia.org/wiki/Mercaptopurine,"National Drug Code Directory:0378-3547-52","DrugBank:DB01033","ChEBI:2208","KEGG Compound:C02380","KEGG Drug:D04931","PubChem Compound:667490","PubChem Substance:46506988","PubChem Substance:5422","Drugs Product Database (DPD):00004723","BindingDB:50200098","ChemSpider:580869","Therapeutic Targets Database:DAP000147","FDA Drug Label at DailyMed:15904472-4c32-4224-95d3-eb131a7ff9c8","ClinicalTrials.gov:NCT00521950","ClinicalTrials.gov:NCT00549848"	Yes	CPIC,"DPWG"	Testing recommended	Testing recommended	22304581;15784872
1;2	chr1:97915614	chr1:97915614	C	T	DPYD*2A	tegafur	DPYD	Toxicity/ADR,Metabolism/PK	1A	Neoplasms	PA145	DPYD	[GRCh37]chr1:97915614	54	2	1	0	Yes	NC_000001.11:g.97450058C>T, NM_000110.3:c.1905+1G>A, XM_005270561.1:c.1794+1G>A, NG_008807.2:g.476002G>A, NC_000001.10:g.97915614C>T, [GRCh37]chr1:97915614, [GRCh38]chr1:97450058, XM_005270562.3:c.1689+1G>A, rs3918290, rs199469548, XM_005270563.1:c.1905+1G>A, XM_005270562.1:c.1689+1G>A, XM_006710397.2:c.1905+1G>A, rs386589337	PA166153760	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	.	.	.	.	.	.	.	.	.	23930673;26603945
1;2	chr11:67352689	chr11:67352689	A	G	GSTP1 rs1695	anthracyclines	GSTP1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	27785604
1;2	chr1:11856378	chr1:11856378	G	A	MTHFR C677T	methotrexate	MTHFR	Dosage,Efficacy,Toxicity/ADR	2A	Neoplasms	PA26551,PA245	CLCN6,MTHFR	[GRCh37]chr1:11856378	121	16	3	0	No	XM_005263463.2:c.419C>T, NC_000001.10:g.11856378G>A, NP_005948.3:p.Ala222Val, [GRCh37]chr1:11856378, rs386545618, XM_005263459.1:c.734C>T, NC_000001.11:g.11796321G>A, XM_005263462.3:c.665C>T, NP_005948.3:p.A222V, rs59514310, XP_005263516.1:p.Ala245Val, XP_005263515.1:p.Ala263Val, XP_005263518.1:p.Ala222Val, XM_011541495.1:c.785C>T, NG_013351.1:g.14783C>T, XM_005263462.1:c.665C>T, XM_005263461.3:c.665C>T, XP_005263519.1:p.Ala222Val, XM_005263461.1:c.665C>T, XP_005263520.1:p.Ala140Val, XM_005263460.3:c.665C>T, XM_005263458.1:c.788C>T, NM_005957.4:c.665C>T, XP_011539797.1:p.Ala262Val, XM_011541496.1:c.788C>T, rs4134713, rs1801133, XP_011539798.1:p.Ala263Val, XM_005263458.2:c.788C>T, XM_005263463.1:c.419C>T, XP_005263517.1:p.Ala222Val, XM_005263460.1:c.665C>T	PA166153644	.	.	.	PA450428	Amethopterin,"Amethopterine","HDMTX","L-Amethopterin","MTX","Methopterin","Methotextrate","Methotrexat","Methotrexate Sodium","Methylaminopterin","Methylaminopterinum","N-Bismethylpteroylglutamic Acid"	Abitrexate,"Antifolan","Arbitrexate","Emtexate","Folex","Ledertrexate","Metatrexan","Methotrate","Mexate","Rheumatrex","Trexall"	.	Web Resource:http://en.wikipedia.org/wiki/Methotrexate,"National Drug Code Directory:67253-320-10","DrugBank:DB00563","PDB:MTX","ChEBI:6837","KEGG Compound:C01937","KEGG Drug:D00142","PubChem Compound:126941","PubChem Substance:46507678","PubChem Substance:7847210","Drugs Product Database (DPD):02244798","BindingDB:18050","ChemSpider:112728","HET:MTX","Therapeutic Targets Database:DNC000933","FDA Drug Label at DailyMed:9c4a4784-b063-4c8f-b915-aeb18cb149be","ClinicalTrials.gov:NCT00445744","ClinicalTrials.gov:NCT00549848","ClinicalTrials.gov:NCT01393405","ClinicalTrials.gov:NCT01876082","ClinicalTrials.gov:NCT01896752"	No	.	.	.	20595278;20514079;19144510
2	chr19:41512841	chr19:41512841	G	T	CYP2B6*6	cyclophosphamide	CYP2B6	Toxicity/ADR	3	Hepatic Veno-Occlusive Disease,Transplantation	PA27103,PA123	CYP2A7P1,CYP2B6	[GRCh37]chr19:41512841	174	12	4	0	Yes	XP_011524849.1:p.Gln172His, NC_000019.10:g.41006936G>T, XM_011526550.1:c.364+2490G>T, XM_005258569.1:c.516G>T, XP_005258626.1:p.Gln172His, NP_000758.1:p.Gln172His, XP_005258627.1:p.Gln172His, XM_011526546.1:c.516G>T, XP_006723113.1:p.Gln172His, XM_011526548.1:c.484+2490G>T, rs57685583, [GRCh38]chr19:41006936, XM_005258570.1:c.516G>T, XM_005258571.1:c.364+2490G>T, XM_011526549.1:c.-75-1G>T, XM_011526547.1:c.516G>T, rs3745274, NG_007929.1:g.20638G>T, NM_000767.4:c.516G>T, XM_006723050.2:c.516G>T, NC_000019.9:g.41512841G>T, XM_005258569.3:c.516G>T, XP_011524848.1:p.Gln172His, rs56308434, [GRCh37.p13]chr19:41512841, NP_000758.1:p.Q172H,Q	PA166155409	.	.	.	PA449165	cyclophosphamide	ASTA,"Asta B 518","CP","CPA","CTX","CY","Clafen","Claphene","Cyclophosphamid","Cyclophosphamide Monohydrate","Cyclophosphamide Sterile","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphoramide","Cyclostin","Cyklofosfamid","Cytophosphan","Cytoxan","Cytoxan Lyoph","Endoxan","Endoxan R","Endoxan-Asta","Endoxana","Endoxanal","Endoxane","Enduxan","Genoxal","Hexadrin","Lyophilized Cytoxan","Mitoxan","Neosar","Procytox","Rcra Waste Number U058","Revimmune","Semdoxan","Sendoxan","Senduxan","Zyklophosphamid"	Procytox for Injection 2000mg Pws Iv (Cyclophosphamide + Sodium Chloride)	Web Resource:http://en.wikipedia.org/wiki/Cyclophosphamide,"National Drug Code Directory:0054-4129-25","DrugBank:DB00531","Chemical Abstracts Service:50-18-0","ChEBI:4027","KEGG Drug:D00287","PubChem Compound:2907","PubChem Substance:148529","PubChem Substance:46505441","Drugs Product Database (DPD):02241797","ChemSpider:2804","Therapeutic Targets Database:DAP000532","FDA Drug Label at DailyMed:1bd19d11-477e-4b4d-8d1d-4b376a403140","FDA Drug Label at DailyMed:367b47d7-c4de-4b39-bd3a-69c29d80396f","ClinicalTrials.gov:NCT00131963","ClinicalTrials.gov:NCT00235235","ClinicalTrials.gov:NCT00352872","ClinicalTrials.gov:NCT00445744","ClinicalTrials.gov:NCT00549848","ClinicalTrials.gov:NCT00589901","ClinicalTrials.gov:NCT00611351","ClinicalTrials.gov:NCT00897871","ClinicalTrials.gov:NCT00994968","ClinicalTrials.gov:NCT01176799","ClinicalTrials.gov:NCT01462253","ClinicalTrials.gov:NCT01540110","ClinicalTrials.gov:NCT01554371","ClinicalTrials.gov:NCT01606878","ClinicalTrials.gov:NCT01690702","ClinicalTrials.gov:NCT01959490"	No	.	.	.	18171905;24128861
2	chr19:41515263	chr19:41515263	A	G	CYP2B6*6	cyclophosphamide	CYP2B6	Toxicity/ADR	3	Transplantation	PA123	CYP2B6	[GRCh37]chr19:41515263	33	6	1	0	Yes	XP_006723113.1:p.Lys262Arg, XP_005258627.1:p.Lys262Arg, XM_011526546.1:c.785A>G, XM_005258569.1:c.785A>G, XM_011526550.1:c.365-2940A>G, NM_000767.4:c.785A>G, XM_011526548.1:c.485-2940A>G, NG_007929.1:g.23060A>G, XM_005258569.3:c.785A>G, NP_000758.1:p.K262R, [GRCh37]chr19:41515263, XM_005258571.1:c.365-2940A>G, XP_011524848.1:p.Lys262Arg, XM_011526549.1:c.194A>G, XM_011526547.1:c.785A>G, XP_005258626.1:p.Lys262Arg, rs2279343, [GRCh38]chr19:41009358, XM_006723050.2:c.785A>G, XP_011524851.1:p.Lys65Arg, NC_000019.9:g.41515263A>G, NC_000019.10:g.41009358A>G, XP_011524849.1:p.Lys262Arg, NP_000758.1:p.Lys262Arg, XM_005258570.1:c.785A>G	PA166155393	CYP2B6	PA166123422;PA166105117;PA166104917;PA166127667;PA166160162	Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6;Annotation of FDA Label for efavirenz and CYP2B6;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6;Annotation of PMDA Label for efavirenz and CYP2B6	PA449165	cyclophosphamide	ASTA,"Asta B 518","CP","CPA","CTX","CY","Clafen","Claphene","Cyclophosphamid","Cyclophosphamide Monohydrate","Cyclophosphamide Sterile","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphoramide","Cyclostin","Cyklofosfamid","Cytophosphan","Cytoxan","Cytoxan Lyoph","Endoxan","Endoxan R","Endoxan-Asta","Endoxana","Endoxanal","Endoxane","Enduxan","Genoxal","Hexadrin","Lyophilized Cytoxan","Mitoxan","Neosar","Procytox","Rcra Waste Number U058","Revimmune","Semdoxan","Sendoxan","Senduxan","Zyklophosphamid"	Procytox for Injection 2000mg Pws Iv (Cyclophosphamide + Sodium Chloride)	Web Resource:http://en.wikipedia.org/wiki/Cyclophosphamide,"National Drug Code Directory:0054-4129-25","DrugBank:DB00531","Chemical Abstracts Service:50-18-0","ChEBI:4027","KEGG Drug:D00287","PubChem Compound:2907","PubChem Substance:148529","PubChem Substance:46505441","Drugs Product Database (DPD):02241797","ChemSpider:2804","Therapeutic Targets Database:DAP000532","FDA Drug Label at DailyMed:1bd19d11-477e-4b4d-8d1d-4b376a403140","FDA Drug Label at DailyMed:367b47d7-c4de-4b39-bd3a-69c29d80396f","ClinicalTrials.gov:NCT00131963","ClinicalTrials.gov:NCT00235235","ClinicalTrials.gov:NCT00352872","ClinicalTrials.gov:NCT00445744","ClinicalTrials.gov:NCT00549848","ClinicalTrials.gov:NCT00589901","ClinicalTrials.gov:NCT00611351","ClinicalTrials.gov:NCT00897871","ClinicalTrials.gov:NCT00994968","ClinicalTrials.gov:NCT01176799","ClinicalTrials.gov:NCT01462253","ClinicalTrials.gov:NCT01540110","ClinicalTrials.gov:NCT01554371","ClinicalTrials.gov:NCT01606878","ClinicalTrials.gov:NCT01690702","ClinicalTrials.gov:NCT01959490"	No	.	.	.	18171905;24128861
1;2	chr10:96741053	chr10:96741053	A	C	CYP2C9*3	cyclophosphamide	CYP2C9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18496131;9241661
1;2	chr10:96541616	chr10:96541616	G	A	CYP2C19*2	cyclophosphamide	CYP2C19	Efficacy	4	Breast Neoplasms	PA124	CYP2C19	[GRCh37]chr10:96541616	133	11	4	0	Yes	NP_000760.1:p.Pro227=, NM_000769.2:c.681G>A, rs116940633, [GRCh37]chr10:96541616, NG_008384.2:g.24154G>A, [GRCh38]chr10:94781859, rs17879456, rs60361278, NC_000010.11:g.94781859G>A, NP_000760.1:p.P227P, rs4244285, NC_000010.10:g.96541616G>A, NM_000769.1:c.681G>A	PA166154053	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	.	.	.	.	.	.	.	.	.	26456622;28976264
1;2	chr16:69745145	chr16:69745145	G	A	NQO1 rs1800566	mitomycin	NQO1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11773862
1;2	chr16:69748869	chr16:69748869	G	A	NQO1 rs1131341	mitomycin	NQO1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11773862
1;2	chr6:18143955	chr6:18143955	C	G	TPMT*2	platinum	TPMT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19898482;23588304
1;2	chr6:18139228	chr6:18139228	C	T	TPMT*3A	platinum	TPMT	Toxicity/ADR	3	Neoplasms	PA356	TPMT	[GRCh37]chr6:18139228	10	1	0	0	Yes	XM_011514840.1:c.391G>A, XP_011513141.1:p.Ala154Thr, rs57650974, NM_000367.3:c.460G>A, NC_000006.12:g.18138997C>T, NP_000358.1:p.A154T, NP_000358.1:p.Ala154Thr, NC_000006.11:g.18139228C>T, rs16880273, rs11568060, XM_011514839.1:c.460G>A, XP_011513142.1:p.Ala131Thr, rs1800460, rs386545583, NG_012137.2:g.21147G>A, [GRCh38]chr6:18138997, [GRCh37]chr6:18139228	PA166156992	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA449014	CACP,"CPDC","CPDD","Cis-DDP","Cis-Diaminedichloroplatinum","Cis-Diamminedichloroplatinum","DDP","DDPT","Diamminedichloroplatinum","Platinum Ammine Chloride","Platinum Ammonium Chloride","Platinum Diamine Dichloride","Trans-DDP","Trans-Diaminedichloroplatinum","Trans-Diamminedichloroplatinum","Trans-Dichlorodiammine Platinum","Trans-Platinumdiammine Dichloride"	Abiplatin,"Biocisplatinum","Briplatin","Carboquone","Cis Pt II","Cismaplat","Cisplatine","Cisplatyl","Citoplationo","Lederplatin","Neoplatin","Plastin","Platamine","Platiblastin","Platidiam","Platinex","Platinol","Platinol-AQ","Platinoxan","Randa"	.	Web Resource:http://en.wikipedia.org/wiki/Cisplatin,"National Drug Code Directory:0015-3072-20","DrugBank:DB00515","Chemical Abstracts Service:15663-27-1","ChEBI:27899","KEGG Compound:C06911","KEGG Drug:D00275","PubChem Compound:441203","PubChem Substance:46504561","PubChem Substance:7847341","Drugs Product Database (DPD):02126613","ChemSpider:389985","Therapeutic Targets Database:DAP000215","ClinicalTrials.gov:NCT00216008","ClinicalTrials.gov:NCT00292955","ClinicalTrials.gov:NCT00541073","ClinicalTrials.gov:NCT00601159","ClinicalTrials.gov:NCT00617656","ClinicalTrials.gov:NCT00705549","ClinicalTrials.gov:NCT00792701","ClinicalTrials.gov:NCT00881114","ClinicalTrials.gov:NCT00967928","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01088906","ClinicalTrials.gov:NCT01110226","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01557959","ClinicalTrials.gov:NCT01714037","ClinicalTrials.gov:NCT01790516","ClinicalTrials.gov:NCT01980667"	No	CPNDS	Informative PGx	Informative PGx	19898482;23588304
1;2	chr6:18130918	chr6:18130918	T	C	TPMT*3A	platinum	TPMT	Toxicity/ADR	3	Drug Toxicity,Neoplasms,Ototoxicity	PA356	TPMT	[GRCh37]chr6:18130918	18	3	0	0	Yes	NC_000006.12:g.18130687T>C, XP_011513141.1:p.Tyr225Cys, rs61510596, [GRCh37]chr6:18130918, XP_011513142.1:p.Tyr217Cys, rs16880254, NP_000358.1:p.Y240C, rs1801205, XM_011514839.1:c.674A>G, NC_000006.11:g.18130918T>C, rs52798150, rs1142345, rs29001646, NG_012137.2:g.29457A>G, NM_000367.3:c.719A>G, XM_011514840.1:c.650A>G, [GRCh38]chr6:18130687, NP_000358.1:p.Tyr240Cys	PA166156978	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA449014	CACP,"CPDC","CPDD","Cis-DDP","Cis-Diaminedichloroplatinum","Cis-Diamminedichloroplatinum","DDP","DDPT","Diamminedichloroplatinum","Platinum Ammine Chloride","Platinum Ammonium Chloride","Platinum Diamine Dichloride","Trans-DDP","Trans-Diaminedichloroplatinum","Trans-Diamminedichloroplatinum","Trans-Dichlorodiammine Platinum","Trans-Platinumdiammine Dichloride"	Abiplatin,"Biocisplatinum","Briplatin","Carboquone","Cis Pt II","Cismaplat","Cisplatine","Cisplatyl","Citoplationo","Lederplatin","Neoplatin","Plastin","Platamine","Platiblastin","Platidiam","Platinex","Platinol","Platinol-AQ","Platinoxan","Randa"	.	Web Resource:http://en.wikipedia.org/wiki/Cisplatin,"National Drug Code Directory:0015-3072-20","DrugBank:DB00515","Chemical Abstracts Service:15663-27-1","ChEBI:27899","KEGG Compound:C06911","KEGG Drug:D00275","PubChem Compound:441203","PubChem Substance:46504561","PubChem Substance:7847341","Drugs Product Database (DPD):02126613","ChemSpider:389985","Therapeutic Targets Database:DAP000215","ClinicalTrials.gov:NCT00216008","ClinicalTrials.gov:NCT00292955","ClinicalTrials.gov:NCT00541073","ClinicalTrials.gov:NCT00601159","ClinicalTrials.gov:NCT00617656","ClinicalTrials.gov:NCT00705549","ClinicalTrials.gov:NCT00792701","ClinicalTrials.gov:NCT00881114","ClinicalTrials.gov:NCT00967928","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01088906","ClinicalTrials.gov:NCT01110226","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01557959","ClinicalTrials.gov:NCT01714037","ClinicalTrials.gov:NCT01790516","ClinicalTrials.gov:NCT01980667"	No	CPNDS	Informative PGx	Informative PGx	19898482;23588304
1;2	chr6:18139228	chr6:18139228	C	T	TPMT*3B	platinum	TPMT	Toxicity/ADR	3	Neoplasms	PA356	TPMT	[GRCh37]chr6:18139228	10	1	0	0	Yes	XM_011514840.1:c.391G>A, XP_011513141.1:p.Ala154Thr, rs57650974, NM_000367.3:c.460G>A, NC_000006.12:g.18138997C>T, NP_000358.1:p.A154T, NP_000358.1:p.Ala154Thr, NC_000006.11:g.18139228C>T, rs16880273, rs11568060, XM_011514839.1:c.460G>A, XP_011513142.1:p.Ala131Thr, rs1800460, rs386545583, NG_012137.2:g.21147G>A, [GRCh38]chr6:18138997, [GRCh37]chr6:18139228	PA166156992	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA449014	CACP,"CPDC","CPDD","Cis-DDP","Cis-Diaminedichloroplatinum","Cis-Diamminedichloroplatinum","DDP","DDPT","Diamminedichloroplatinum","Platinum Ammine Chloride","Platinum Ammonium Chloride","Platinum Diamine Dichloride","Trans-DDP","Trans-Diaminedichloroplatinum","Trans-Diamminedichloroplatinum","Trans-Dichlorodiammine Platinum","Trans-Platinumdiammine Dichloride"	Abiplatin,"Biocisplatinum","Briplatin","Carboquone","Cis Pt II","Cismaplat","Cisplatine","Cisplatyl","Citoplationo","Lederplatin","Neoplatin","Plastin","Platamine","Platiblastin","Platidiam","Platinex","Platinol","Platinol-AQ","Platinoxan","Randa"	.	Web Resource:http://en.wikipedia.org/wiki/Cisplatin,"National Drug Code Directory:0015-3072-20","DrugBank:DB00515","Chemical Abstracts Service:15663-27-1","ChEBI:27899","KEGG Compound:C06911","KEGG Drug:D00275","PubChem Compound:441203","PubChem Substance:46504561","PubChem Substance:7847341","Drugs Product Database (DPD):02126613","ChemSpider:389985","Therapeutic Targets Database:DAP000215","ClinicalTrials.gov:NCT00216008","ClinicalTrials.gov:NCT00292955","ClinicalTrials.gov:NCT00541073","ClinicalTrials.gov:NCT00601159","ClinicalTrials.gov:NCT00617656","ClinicalTrials.gov:NCT00705549","ClinicalTrials.gov:NCT00792701","ClinicalTrials.gov:NCT00881114","ClinicalTrials.gov:NCT00967928","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01088906","ClinicalTrials.gov:NCT01110226","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01557959","ClinicalTrials.gov:NCT01714037","ClinicalTrials.gov:NCT01790516","ClinicalTrials.gov:NCT01980667"	No	CPNDS	Informative PGx	Informative PGx	19898482;23588304
1;2	chr6:18130918	chr6:18130918	T	C	TPMT*3C	platinum	TPMT	Toxicity/ADR	3	Drug Toxicity,Neoplasms,Ototoxicity	PA356	TPMT	[GRCh37]chr6:18130918	18	3	0	0	Yes	NC_000006.12:g.18130687T>C, XP_011513141.1:p.Tyr225Cys, rs61510596, [GRCh37]chr6:18130918, XP_011513142.1:p.Tyr217Cys, rs16880254, NP_000358.1:p.Y240C, rs1801205, XM_011514839.1:c.674A>G, NC_000006.11:g.18130918T>C, rs52798150, rs1142345, rs29001646, NG_012137.2:g.29457A>G, NM_000367.3:c.719A>G, XM_011514840.1:c.650A>G, [GRCh38]chr6:18130687, NP_000358.1:p.Tyr240Cys	PA166156978	TPMT	PA166121251;PA166104782;PA166104853;PA166104810;PA166104838;PA166127635;PA166127690;PA166127720;PA166123530	Annotation of EMA Label for mercaptopurine and TPMT;Annotation of FDA Label for azathioprine and TPMT;Annotation of FDA Label for cisplatin and TPMT;Annotation of FDA Label for mercaptopurine and TPMT;Annotation of FDA Label for thioguanine and TPMT;Annotation of HCSC Label for azathioprine and TPMT;Annotation of HCSC Label for mercaptopurine and TPMT;Annotation of HCSC Label for thioguanine and TPMT;Annotation of PMDA Label for azathioprine and TPMT	PA449014	CACP,"CPDC","CPDD","Cis-DDP","Cis-Diaminedichloroplatinum","Cis-Diamminedichloroplatinum","DDP","DDPT","Diamminedichloroplatinum","Platinum Ammine Chloride","Platinum Ammonium Chloride","Platinum Diamine Dichloride","Trans-DDP","Trans-Diaminedichloroplatinum","Trans-Diamminedichloroplatinum","Trans-Dichlorodiammine Platinum","Trans-Platinumdiammine Dichloride"	Abiplatin,"Biocisplatinum","Briplatin","Carboquone","Cis Pt II","Cismaplat","Cisplatine","Cisplatyl","Citoplationo","Lederplatin","Neoplatin","Plastin","Platamine","Platiblastin","Platidiam","Platinex","Platinol","Platinol-AQ","Platinoxan","Randa"	.	Web Resource:http://en.wikipedia.org/wiki/Cisplatin,"National Drug Code Directory:0015-3072-20","DrugBank:DB00515","Chemical Abstracts Service:15663-27-1","ChEBI:27899","KEGG Compound:C06911","KEGG Drug:D00275","PubChem Compound:441203","PubChem Substance:46504561","PubChem Substance:7847341","Drugs Product Database (DPD):02126613","ChemSpider:389985","Therapeutic Targets Database:DAP000215","ClinicalTrials.gov:NCT00216008","ClinicalTrials.gov:NCT00292955","ClinicalTrials.gov:NCT00541073","ClinicalTrials.gov:NCT00601159","ClinicalTrials.gov:NCT00617656","ClinicalTrials.gov:NCT00705549","ClinicalTrials.gov:NCT00792701","ClinicalTrials.gov:NCT00881114","ClinicalTrials.gov:NCT00967928","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01088906","ClinicalTrials.gov:NCT01110226","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01557959","ClinicalTrials.gov:NCT01714037","ClinicalTrials.gov:NCT01790516","ClinicalTrials.gov:NCT01980667"	No	CPNDS	Informative PGx	Informative PGx	19898482;23588304
1;2	chr19:45854919	chr19:45854919	T	G	ERCC2 rs13181	platinum	ERCC2	Efficacy	4	Mesothelioma	PA27848,PA142671588	ERCC2,KLC3	[GRCh37]chr19:45854919	27	5	0	0	No	XM_005258640.1:c.2017A>C, NC_000019.10:g.45351661T>G, XM_005258536.3:c.*128T>G, XP_005258698.1:p.Lys505Gln, XM_005258639.1:c.2179A>C, rs17285142, XM_011526611.1:c.2173A>C, XM_005258537.1:c.*128T>G, XM_005258641.1:c.1513A>C, rs17359310, NM_000400.3:c.2251A>C, rs60606175, XM_005258536.1:c.*128T>G, NC_000019.9:g.45854919T>G, XP_005258696.1:p.Lys727Gln, rs1052559, NP_000391.1:p.K751Q, rs17355147, NP_000391.1:p.Lys751Gln, rs13181, rs3170171, NG_007067.2:g.23927A>C, XP_011524913.1:p.Lys725Gln, XM_005258539.1:c.*304T>G, NM_177417.2:c.*304T>G, rs3859422, XM_005258538.1:c.*304T>G, XP_005258697.1:p.Lys673Gln, [GRCh37]chr19:45854919	PA166155343	.	.	.	.	.	.	.	.	.	.	.	.	19434073
1;2	chr11:67352689	chr11:67352689	A	G	GSTP1 rs1695	platinum	GSTP1	Efficacy	3	Neoplasms	PA29028	GSTP1	[GRCh37]chr11:67352689	59	11	4	0	No	rs17353321, NP_000843.1:p.I105V, rs17856342, rs56971933, NG_012075.1:g.6624A>G, NP_000843.1:p.Ile105Val, rs11553891, NM_000852.3:c.313A>G, rs2230827, XM_005273958.1:c.313A>G, rs947894, rs1695, NC_000011.10:g.67585218A>G, rs1138257, rs4609, XP_005274015.1:p.Ile105Val, NC_000011.9:g.67352689A>G, [GRCh37]chr11:67352689	PA166154249	.	.	.	PA164713176	.	.	.	.	No	.	.	.	18854777
1;2	chr19:44055726	chr19:44055726	T	C	XRCC1 Q399R	platinum	XRCC1	Efficacy	2B	Carcinoma, Non-Small-Cell Lung,Colorectal Neoplasms,Neoplasms,Ovarian Neoplasms,Pancreatic Neoplasms,Uterine Cervical Neoplasms	PA369	XRCC1	[GRCh37]chr19:44055726	29	3	1	0	No	rs57378728, rs17435395, [GRCh37]chr19:44055726, NP_006288.2:p.Q399R, rs25487, NG_033799.1:g.29005A>G, NC_000019.10:g.43551574T>C, NM_006297.2:c.1196A>G, rs11553658, NP_006288.2:p.Gln399Arg, NC_000019.9:g.44055726T>C, rs3817410, rs386493716	PA166155346	.	.	.	.	.	.	.	.	.	.	.	.	16875718;25025378
1;2	chr2:234668879	chr2:234668880	-	AT	UGT1A1*28	irinotecan	UGT1A1	Toxicity/ADR	2A	Neoplasms	PA420,PA37174,PA37178,PA37179,PA37180,PA37181,PA37182,PA37183,PA419	UGT1A1,UGT1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,UGT1A9	[GRCh37]chr2:234668881_234668882	154	14	3	0	Yes	[GRCh37]chr2:234668881_234668882, rs8175347	PA166159020	.	.	.	PA450085	Irinotecan Hcl,"Irinotecan Hydrochloride","Irinotecan Hydrochloride Trihydrate","Irinotecanum [INN-Latin]","irinotecan"	CP0,"Camptosar","IRINOTECAN, CPT-11"	.	Web Resource:http://en.wikipedia.org/wiki/Irinotecan,"National Drug Code Directory:0703-4432-11","DrugBank:DB00762","KEGG Drug:D08086","PubChem Compound:60838","PubChem Substance:217212","PubChem Substance:46505871","Drugs Product Database (DPD):02231622","ChemSpider:54825","Therapeutic Targets Database:DAP001339","FDA Drug Label at DailyMed:e98886aa-933c-430f-bb56-f1eb3862aae4","ClinicalTrials.gov:NCT00026195","ClinicalTrials.gov:NCT00074321","ClinicalTrials.gov:NCT00140036","ClinicalTrials.gov:NCT00268398","ClinicalTrials.gov:NCT00433550","ClinicalTrials.gov:NCT00467142","ClinicalTrials.gov:NCT00559676","ClinicalTrials.gov:NCT00559741","ClinicalTrials.gov:NCT00654160","ClinicalTrials.gov:NCT00682786","ClinicalTrials.gov:NCT00689624","ClinicalTrials.gov:NCT00731276","ClinicalTrials.gov:NCT00813072","ClinicalTrials.gov:NCT00813163","ClinicalTrials.gov:NCT00836277","ClinicalTrials.gov:NCT00936832","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01205711","ClinicalTrials.gov:NCT01282658","ClinicalTrials.gov:NCT01501669","ClinicalTrials.gov:NCT01639326","ClinicalTrials.gov:NCT01855061","ClinicalTrials.gov:NCT01867892"	No	DPWG,"PRO"	Actionable PGx	Testing recommended	22676194;26830078;28367249
1;2	chr2:234669144	chr2:234669144	G	A	UGT1A1*6	irinotecan	UGT1A1	Other	2A	Neoplasms	PA420,PA37174,PA37178,PA37179,PA37180,PA37181,PA37182,PA37183,PA419	UGT1A1,UGT1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,UGT1A9	[GRCh37]chr2:234669144	36	6	2	0	Yes	XR_241240.1:n.1023-6536G>A, XR_241239.1:n.233G>A, NP_000454.1:p.G71R, rs4148323, NM_019076.4:c.856-6536G>A, NG_033238.1:g.5226G>A, XR_241238.1:n.924-6536G>A, NP_000454.1:p.Gly71Arg, [GRCh37]chr2:234669144, NC_000002.11:g.234669144G>A, NM_019075.2:c.856-6536G>A, NM_007120.2:c.868-6536G>A, XR_241241.1:n.942-6536G>A, NC_000002.12:g.233760498G>A, NM_021027.2:c.856-6536G>A, NM_001072.3:c.862-6536G>A, NM_019093.2:c.868-6536G>A, rs113525835, [GRCh38]chr2:233760498, NM_000463.2:c.211G>A, NG_002601.2:g.175755G>A, rs58105808, rs58585123, rs34360183, NM_205862.1:c.61-6536G>A, NM_019077.2:c.856-6536G>A, NM_019078.1:c.868-6536G>A	PA166155721	.	.	.	PA450085	Irinotecan Hcl,"Irinotecan Hydrochloride","Irinotecan Hydrochloride Trihydrate","Irinotecanum [INN-Latin]","irinotecan"	CP0,"Camptosar","IRINOTECAN, CPT-11"	.	Web Resource:http://en.wikipedia.org/wiki/Irinotecan,"National Drug Code Directory:0703-4432-11","DrugBank:DB00762","KEGG Drug:D08086","PubChem Compound:60838","PubChem Substance:217212","PubChem Substance:46505871","Drugs Product Database (DPD):02231622","ChemSpider:54825","Therapeutic Targets Database:DAP001339","FDA Drug Label at DailyMed:e98886aa-933c-430f-bb56-f1eb3862aae4","ClinicalTrials.gov:NCT00026195","ClinicalTrials.gov:NCT00074321","ClinicalTrials.gov:NCT00140036","ClinicalTrials.gov:NCT00268398","ClinicalTrials.gov:NCT00433550","ClinicalTrials.gov:NCT00467142","ClinicalTrials.gov:NCT00559676","ClinicalTrials.gov:NCT00559741","ClinicalTrials.gov:NCT00654160","ClinicalTrials.gov:NCT00682786","ClinicalTrials.gov:NCT00689624","ClinicalTrials.gov:NCT00731276","ClinicalTrials.gov:NCT00813072","ClinicalTrials.gov:NCT00813163","ClinicalTrials.gov:NCT00836277","ClinicalTrials.gov:NCT00936832","ClinicalTrials.gov:NCT01003964","ClinicalTrials.gov:NCT01205711","ClinicalTrials.gov:NCT01282658","ClinicalTrials.gov:NCT01501669","ClinicalTrials.gov:NCT01639326","ClinicalTrials.gov:NCT01855061","ClinicalTrials.gov:NCT01867892"	No	DPWG,"PRO"	Actionable PGx	Testing recommended	24519753;17627617;26857783
1;2	chr2:95539307	chr2:95539307	A	G	TEKT4 A541G	paclitaxel	TEKT4 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	24823476
1;2	chr2:95539313	chr2:95539313	A	G	TEKT4 A547G	paclitaxel	TEKT4 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	24823476
1;2	chr2:234668879	chr2:234668880	-	AT	UGT1A1*28	etoposide	UGT1A1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	26313268
1;2	chr2:234669144	chr2:234669144	G	A	UGT1A1*6	etoposide	UGT1A1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	25055799
1;2	chr7:99367825	chr7:99367825	T	C	CYP3A4*4	etoposide	CYP3A4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12181418;12439220
1;2	chr1:97915614	chr1:97915614	C	T	DPYD*2A	fluorouracil	DPYD	Efficacy	3	Neoplasms	PA145	DPYD	[GRCh37]chr1:97915614	54	2	1	0	Yes	NC_000001.11:g.97450058C>T, NM_000110.3:c.1905+1G>A, XM_005270561.1:c.1794+1G>A, NG_008807.2:g.476002G>A, NC_000001.10:g.97915614C>T, [GRCh37]chr1:97915614, [GRCh38]chr1:97450058, XM_005270562.3:c.1689+1G>A, rs3918290, rs199469548, XM_005270563.1:c.1905+1G>A, XM_005270562.1:c.1689+1G>A, XM_006710397.2:c.1905+1G>A, rs386589337	PA166153760	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	PA128406956	.	5 Fluorouracil,"Adrucil","Arumel","Carac","Carzonal","Effluderm","Efudex","Efudix","Efurix","FU","Fluoroblastin","Fluoroplex","Fluracil","Fluracilum","Fluri","Fluril","Fluro Uracil","Flurouracil","Ftoruracil","Kecimeton","Phthoruracil","Phtoruracil","Queroplex","Timazin","URF","Ulup"	.	Web Resource:http://en.wikipedia.org/wiki/Fluorouracil,"National Drug Code Directory:0703-3015-13","DrugBank:DB00544","PDB:URF","Chemical Abstracts Service:51-21-8","ChEBI:46345","KEGG Compound:C07649","KEGG Drug:D00584","PubChem Compound:3385","PubChem Substance:46508557","PubChem Substance:7847650","Drugs Product Database (DPD):02182742","ChemSpider:3268","HET:URF","Therapeutic Targets Database:DAP000829","FDA Drug Label at DailyMed:e0794add-67a7-4308-93e9-f889472716cc","ClinicalTrials.gov:NCT00074321","ClinicalTrials.gov:NCT00130936","ClinicalTrials.gov:NCT00131599","ClinicalTrials.gov:NCT00140036","ClinicalTrials.gov:NCT00268398","ClinicalTrials.gov:NCT00433550","ClinicalTrials.gov:NCT00467142","ClinicalTrials.gov:NCT00559676","ClinicalTrials.gov:NCT00559741","ClinicalTrials.gov:NCT00589901","ClinicalTrials.gov:NCT00645866","ClinicalTrials.gov:NCT00654160","ClinicalTrials.gov:NCT00682786","ClinicalTrials.gov:NCT00689624","ClinicalTrials.gov:NCT00737373","ClinicalTrials.gov:NCT00838370","ClinicalTrials.gov:NCT00849615","ClinicalTrials.gov:NCT00884767","ClinicalTrials.gov:NCT00936832","ClinicalTrials.gov:NCT00938470","ClinicalTrials.gov:NCT01063192","ClinicalTrials.gov:NCT01068327","ClinicalTrials.gov:NCT01158274","ClinicalTrials.gov:NCT01205711","ClinicalTrials.gov:NCT01206465","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01307956","ClinicalTrials.gov:NCT01501669","ClinicalTrials.gov:NCT01641458","ClinicalTrials.gov:NCT01705106","ClinicalTrials.gov:NCT01867892"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	29134491;17165084;23930673
1;2	chr1:11856378	chr1:11856378	G	A	MTHFR C677T	fluorouracil	MTHFR	Efficacy,Toxicity/ADR	3	Colonic Neoplasms	PA26551,PA245	CLCN6,MTHFR	[GRCh37]chr1:11856378	121	16	3	0	No	XM_005263463.2:c.419C>T, NC_000001.10:g.11856378G>A, NP_005948.3:p.Ala222Val, [GRCh37]chr1:11856378, rs386545618, XM_005263459.1:c.734C>T, NC_000001.11:g.11796321G>A, XM_005263462.3:c.665C>T, NP_005948.3:p.A222V, rs59514310, XP_005263516.1:p.Ala245Val, XP_005263515.1:p.Ala263Val, XP_005263518.1:p.Ala222Val, XM_011541495.1:c.785C>T, NG_013351.1:g.14783C>T, XM_005263462.1:c.665C>T, XM_005263461.3:c.665C>T, XP_005263519.1:p.Ala222Val, XM_005263461.1:c.665C>T, XP_005263520.1:p.Ala140Val, XM_005263460.3:c.665C>T, XM_005263458.1:c.788C>T, NM_005957.4:c.665C>T, XP_011539797.1:p.Ala262Val, XM_011541496.1:c.788C>T, rs4134713, rs1801133, XP_011539798.1:p.Ala263Val, XM_005263458.2:c.788C>T, XM_005263463.1:c.419C>T, XP_005263517.1:p.Ala222Val, XM_005263460.1:c.665C>T	PA166153644	.	.	.	.	.	.	.	.	.	.	.	.	19144510;29134491;10462625
1;2	chr1:98348885	chr1:98348885	G	A	DPYD*9A	fluorouracil	DPYD	Toxicity/ADR	3	Neoplasms	PA145	DPYD	[GRCh37]chr1:98348885	24	1	0	0	Yes	XM_005270564.1:c.85C=, [GRCh37]chr1:98348885, NP_001153773.1:p.Cys29Arg, XP_005270620.1:p.Arg29=, XM_006710397.2:c.85T>C, XM_005270563.1:c.85C>T, rs199469510, rs3211355, NC_000001.11:g.97883329A=, NM_001160301.1:c.85T>C, rs57596852, rs1801265, XM_005270563.1:c.85C=, NP_000101.2:p.Cys29=, NP_000101.2:p.Cys29Arg, NM_000110.3:c.85T=, XP_005270619.1:p.Arg29=, XM_005270562.3:c.85T=, rs52823090, XM_005270561.1:c.39+37555C>T, XM_005270561.1:c.39+37555T>C, XP_006710460.1:p.Cys29Arg, NP_000101.2:p.C29R, XM_005270562.3:c.85T>C, XM_005270564.1:c.85C>T, XM_005270562.1:c.85C>T, NC_000001.10:g.98348885G>A, NG_008807.2:g.42731T=, NP_001153773.1:p.Cys29=, XP_005270619.1:p.Arg29Cys, NG_008807.2:g.42731T>C, NM_000110.3:c.85T>C, XP_005270619.2:p.Cys29Arg, XP_005270621.1:p.Arg29=, NC_000001.11:g.97883329A>G, XP_006710460.1:p.Cys29=, XP_005270620.1:p.Arg29Cys, [GRCh38]chr1:97883329, XP_005270621.1:p.Arg29Cys, XM_006710397.2:c.85T=, XM_005270562.1:c.85C=, NC_000001.10:g.98348885G=, XP_005270619.2:p.Cys29=, NM_001160301.1:c.85T=	PA166153648	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	PA128406956	.	5 Fluorouracil,"Adrucil","Arumel","Carac","Carzonal","Effluderm","Efudex","Efudix","Efurix","FU","Fluoroblastin","Fluoroplex","Fluracil","Fluracilum","Fluri","Fluril","Fluro Uracil","Flurouracil","Ftoruracil","Kecimeton","Phthoruracil","Phtoruracil","Queroplex","Timazin","URF","Ulup"	.	Web Resource:http://en.wikipedia.org/wiki/Fluorouracil,"National Drug Code Directory:0703-3015-13","DrugBank:DB00544","PDB:URF","Chemical Abstracts Service:51-21-8","ChEBI:46345","KEGG Compound:C07649","KEGG Drug:D00584","PubChem Compound:3385","PubChem Substance:46508557","PubChem Substance:7847650","Drugs Product Database (DPD):02182742","ChemSpider:3268","HET:URF","Therapeutic Targets Database:DAP000829","FDA Drug Label at DailyMed:e0794add-67a7-4308-93e9-f889472716cc","ClinicalTrials.gov:NCT00074321","ClinicalTrials.gov:NCT00130936","ClinicalTrials.gov:NCT00131599","ClinicalTrials.gov:NCT00140036","ClinicalTrials.gov:NCT00268398","ClinicalTrials.gov:NCT00433550","ClinicalTrials.gov:NCT00467142","ClinicalTrials.gov:NCT00559676","ClinicalTrials.gov:NCT00559741","ClinicalTrials.gov:NCT00589901","ClinicalTrials.gov:NCT00645866","ClinicalTrials.gov:NCT00654160","ClinicalTrials.gov:NCT00682786","ClinicalTrials.gov:NCT00689624","ClinicalTrials.gov:NCT00737373","ClinicalTrials.gov:NCT00838370","ClinicalTrials.gov:NCT00849615","ClinicalTrials.gov:NCT00884767","ClinicalTrials.gov:NCT00936832","ClinicalTrials.gov:NCT00938470","ClinicalTrials.gov:NCT01063192","ClinicalTrials.gov:NCT01068327","ClinicalTrials.gov:NCT01158274","ClinicalTrials.gov:NCT01205711","ClinicalTrials.gov:NCT01206465","ClinicalTrials.gov:NCT01283204","ClinicalTrials.gov:NCT01307956","ClinicalTrials.gov:NCT01501669","ClinicalTrials.gov:NCT01641458","ClinicalTrials.gov:NCT01705106","ClinicalTrials.gov:NCT01867892"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	23603345;26603945
1;2	chr1:97981395	chr1:97981395	T	C	DPYD*5	fluorouracil	DPYD	Efficacy,Toxicity/ADR,Metabolism/PK	3	Neoplasms	PA145	DPYD	[GRCh37]chr1:97981395	22	1	0	0	Yes	NP_000101.2:p.Ile543Val, XP_005270618.1:p.Ile506Val, XM_005270562.3:c.1524+33721A>G, rs17116825, NP_000101.2:p.I543V, XP_005270621.1:p.Ile543Val, XM_005270563.1:c.1627A>G, NC_000001.10:g.97981395T>C, XP_005270620.1:p.Ile543Val, XM_005270564.1:c.1627A>G, rs199469541, rs1801159, rs117999026, NG_008807.2:g.410221A>G, NM_000110.3:c.1627A>G, XM_006710397.2:c.1627A>G, [GRCh37]chr1:97981395, XM_005270562.1:c.1524+33721A>G, [GRCh38]chr1:97515839, XP_006710460.1:p.Ile543Val, NC_000001.11:g.97515839T>C, rs58945530, XM_005270561.1:c.1516A>G, rs386545620	PA166153646	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	.	.	.	.	.	.	.	.	.	29441806;18452418
1;2	chr1:97770920	chr1:97770920	C	T	DPYD*6	fluorouracil	DPYD	Toxicity/ADR,Metabolism/PK	3	Neoplasms	PA145	DPYD	[GRCh37]chr1:97770920	18	1	0	0	Yes	XM_006710397.2:c.2194G>A, XP_005270618.1:p.Val695Ile, NM_000110.3:c.2194G>A, [GRCh38]chr1:97305364, rs199469554, XM_005270562.1:c.1978G>A, XM_005270561.1:c.2083G>A, XP_005270619.2:p.Val660Ile, NC_000001.10:g.97770920C>T, NG_008807.2:g.620696G>A, XP_005270619.1:p.Val660Ile, XM_005270562.3:c.1978G>A, NP_000101.2:p.Val732Ile, XP_006710460.1:p.Val732Ile, rs12720468, rs12720467, [GRCh37]chr1:97770920, XM_005270563.1:c.2194G>A, NC_000001.11:g.97305364C>T, NR_046590.1:n.129-825C>T, XP_005270620.1:p.Val732Ile, NP_000101.2:p.V732I, rs1801160	PA166153647	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	.	.	.	.	.	.	.	.	.	17828463;17417073
1;2	chr1:98165091	chr1:98165091	T	C	DPYD rs2297595	fluorouracil	DPYD	Toxicity/ADR,Metabolism/PK	3	Neoplasms	PA145	DPYD	[GRCh37]chr1:98165091	28	1	0	0	No	XP_005270619.2:p.Met166Val, XM_005270561.1:c.385A>G, XP_005270621.1:p.Met166Val, [GRCh37]chr1:98165091, XM_005270562.1:c.496A>G, NC_000001.10:g.98165091T>C, XP_005270619.1:p.Met166Val, XM_005270564.1:c.496A>G, rs118014431, rs199469517, XP_005270618.1:p.Met129Val, NG_008807.2:g.226525A>G, rs2297595, NC_000001.11:g.97699535T>C, rs61243782, XM_006710397.2:c.496A>G, XP_006710460.1:p.Met166Val, rs52827192, NP_000101.2:p.M166V, NP_000101.2:p.Met166Val, XM_005270563.1:c.496A>G, XM_005270562.3:c.496A>G, XP_005270620.1:p.Met166Val, NM_000110.3:c.496A>G	PA166153696	DPYD	PA166104905;PA166104802;PA166104807;PA166127644;PA166127674;PA166123531;PA166123539	Annotation of EMA Label for capecitabine and DPYD;Annotation of FDA Label for capecitabine and DPYD;Annotation of FDA Label for fluorouracil and DPYD;Annotation of HCSC Label for capecitabine and DPYD;Annotation of HCSC Label for fluorouracil and DPYD;Annotation of PMDA Label for capecitabine and DPYD;Annotation of PMDA Label for fluorouracil and DPYD	.	.	.	.	.	.	.	.	.	24037119;17848752
1;2	chr22:42526694	chr22:42526694	G	A	CYP2D6*10	tamoxifen	CYP2D6	Efficacy,Metabolism/PK	1A	Breast Neoplasms	.	.	.	.	.	.	.	.	.	.	CYP2D6	PA166104899;PA166122966;PA166119827;PA166123414;PA166129447;PA166122967;PA166104930;PA166104915;PA166122487;PA166122947;PA166123410;PA166115435;PA166123408;PA166104856;PA166127662;PA166104839;PA166161219;PA166104827;PA166160054;PA166177479;PA166104813;PA166104787;PA166104852;PA166104875;PA166104815;PA166104916;PA166122971;PA166104862;PA166177483;PA166169882;PA166104886;PA166105113;PA166104820;PA166105010;PA166123487;PA166105012;PA166122972;PA166153432;PA166104788;PA166104835;PA166104854;PA166177509;PA166104869;PA166170929;PA166104887;PA166104879;PA166104836;PA166177514;PA166104868;PA166105028;PA166104880;PA166104888;PA166105211;PA166160052;PA166104864;PA166104893;PA166104870;PA166104837;PA166104798;PA166104812;PA166104811;PA166105232;PA166104793;PA166170935;PA166160672;PA166104822;PA166104829;PA166104805;PA166104830;PA166104806;PA166104799;PA166104857;PA166177521;PA166170052;PA166104847;PA166122607;PA166127628;PA166127631;PA166127633;PA166127646;PA166127654;PA166127659;PA166127673;PA166127675;PA166127691;PA166127697;PA166127704;PA166127708;PA166127718;PA166127719;PA166127721;PA166127731;PA166123528;PA166160226;PA166160709;PA166160669;PA166160712;PA166123541;PA166160845;PA166160850;PA166123549	Annotation of EMA Label for aripiprazole and CYP2D6,CYP3A4;Annotation of EMA Label for darifenacin and CYP2D6;Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6;Annotation of EMA Label for dronedarone and CYP2D6,CYP3A4;Annotation of EMA Label for eliglustat and CYP2D6;Annotation of EMA Label for fesoterodine and CYP2D6;Annotation of EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR;Annotation of EMA Label for olanzapine and CYP1A2,CYP2D6;Annotation of EMA Label for propranolol and CYP2D6;Annotation of EMA Label for ranolazine and CYP2D6;Annotation of EMA Label for ritonavir and CYP2D6,CYP3A4;Annotation of EMA Label for timolol and CYP2D6;Annotation of EMA Label for vortioxetine and CYP2D6;Annotation of FDA Label for amitriptyline and CYP2D6;Annotation of FDA Label for arformoterol and CYP2D6,UGT1A1;Annotation of FDA Label for aripiprazole and CYP2D6;Annotation of FDA Label for aripiprazole lauroxil and CYP2D6;Annotation of FDA Label for atomoxetine and CYP2D6;Annotation of FDA Label for brexpiprazole and CYP2D6;Annotation of FDA Label for cariprazine and CYP2D6;Annotation of FDA Label for carvedilol and CYP2D6;Annotation of FDA Label for cevimeline and CYP2D6;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clomipramine and CYP2D6;Annotation of FDA Label for clozapine and CYP2D6;Annotation of FDA Label for codeine and CYP2D6;Annotation of FDA Label for darifenacin and CYP2D6;Annotation of FDA Label for desipramine and CYP2D6;Annotation of FDA Label for desvenlafaxine and CYP2D6;Annotation of FDA Label for deutetrabenazine and CYP2D6;Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6;Annotation of FDA Label for donepezil and CYP2D6;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for duloxetine and CYP2D6;Annotation of FDA Label for eliglustat and CYP2D6;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for fesoterodine and CYP2D6;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6;Annotation of FDA Label for fluoxetine and CYP2D6;Annotation of FDA Label for fluvoxamine and CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for galantamine and CYP2D6;Annotation of FDA Label for gefitinib and CYP2D6;Annotation of FDA Label for iloperidone and CYP2D6;Annotation of FDA Label for imipramine and CYP2D6;Annotation of FDA Label for metoprolol and CYP2D6;Annotation of FDA Label for mirabegron and CYP2D6;Annotation of FDA Label for modafinil and CYP2D6;Annotation of FDA Label for nebivolol and CYP2D6;Annotation of FDA Label for nefazodone and CYP2D6;Annotation of FDA Label for nortriptyline and CYP2D6;Annotation of FDA Label for ondansetron and CYP2D6;Annotation of FDA Label for palonosetron and CYP2D6;Annotation of FDA Label for paroxetine and CYP2D6;Annotation of FDA Label for perphenazine and CYP2D6;Annotation of FDA Label for pimozide and CYP2D6;Annotation of FDA Label for propafenone and CYP2D6;Annotation of FDA Label for propranolol and CYP2D6;Annotation of FDA Label for protriptyline and CYP2D6;Annotation of FDA Label for quinidine and CYP2D6;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for risperidone and CYP2D6;Annotation of FDA Label for rucaparib and CYP1A2,CYP2D6;Annotation of FDA Label for tamsulosin and CYP2D6;Annotation of FDA Label for terbinafine and CYP2D6;Annotation of FDA Label for tetrabenazine and CYP2D6;Annotation of FDA Label for thioridazine and CYP2D6;Annotation of FDA Label for tiotropium and CYP2D6;Annotation of FDA Label for tolterodine and CYP2D6;Annotation of FDA Label for tramadol and CYP2D6;Annotation of FDA Label for trimipramine and CYP2D6;Annotation of FDA Label for umeclidinium and CYP2D6;Annotation of FDA Label for valbenazine and CYP2D6;Annotation of FDA Label for venlafaxine and CYP2D6;Annotation of FDA Label for vortioxetine and CYP2D6;Annotation of HCSC Label for acetaminophen,tramadol and CYP2D6;Annotation of HCSC Label for aripiprazole and CYP2D6;Annotation of HCSC Label for atomoxetine and CYP2D6;Annotation of HCSC Label for carvedilol and CYP2D6;Annotation of HCSC Label for codeine and CYP2D6;Annotation of HCSC Label for darifenacin and CYP2D6;Annotation of HCSC Label for fesoterodine and CYP2D6;Annotation of HCSC Label for galantamine and CYP2D6;Annotation of HCSC Label for metoprolol and CYP2D6;Annotation of HCSC Label for nortriptyline and CYP2D6;Annotation of HCSC Label for propafenone and CYP2D6;Annotation of HCSC Label for risperidone and CYP2D6;Annotation of HCSC Label for tamoxifen and CYP2D6,ESR1,ESR2;Annotation of HCSC Label for tetrabenazine and CYP2D6;Annotation of HCSC Label for tolterodine and CYP2D6;Annotation of HCSC Label for vortioxetine and CYP2D6;Annotation of PMDA Label for atomoxetine and CYP2D6;Annotation of PMDA Label for codeine and CYP2D6;Annotation of PMDA Label for eliglustat and CYP2D6;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for fesoterodine and CYP2D6;Annotation of PMDA Label for gefitinib and CYP2D6,EGFR;Annotation of PMDA Label for perphenazine and CYP2D6;Annotation of PMDA Label for tetrabenazine and CYP2D6;Annotation of PMDA Label for tolterodine and CYP2D6	PA451581	Tamoxifen Citrate,"Tamoxifene [INN-French]","Tamoxifeno [INN-Spanish]","Tamoxifenum [INN-Latin]","Trans-Tamoxifen"	Apo-Tamox,"Citofen","Crisafeno","Diemon","Gen-Tamoxifen","Istubol","Kessar","Noltam","Nolvadex","Nolvadex-D","Nourytam","Novo-Tamoxifen","Oncomox","PMS-Tamoxifen","Retaxim","Tamizam","Tamofen","Tamone","Tamoxasta","Tamoxen","Valodex","Zemide"	.	Web Resource:http://en.wikipedia.org/wiki/Tamoxifen,"National Drug Code Directory:0378-0144-91","DrugBank:DB00675","PDB:OHT","Chemical Abstracts Service:54965-24-1","ChEBI:9396","KEGG Compound:C07108","KEGG Drug:D00966","PubChem Compound:2733526","PubChem Substance:46505515","PubChem Substance:9319","IUPHAR Ligand:1016","Drugs Product Database (DPD):02237460","BindingDB:20607","ChemSpider:2015313","HET:OHT","Therapeutic Targets Database:DAP000108","FDA Drug Label at DailyMed:7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","ClinicalTrials.gov:NCT00228930","ClinicalTrials.gov:NCT00764322","ClinicalTrials.gov:NCT00830973","ClinicalTrials.gov:NCT00873366","ClinicalTrials.gov:NCT00886535","ClinicalTrials.gov:NCT01127295","ClinicalTrials.gov:NCT01169792","ClinicalTrials.gov:NCT01181518","ClinicalTrials.gov:NCT01192308","ClinicalTrials.gov:NCT01196936","ClinicalTrials.gov:NCT01220076","ClinicalTrials.gov:NCT01658566"	Yes	CPIC,"DPWG"	Testing required	Testing required	18294285;19596663;25701109
1;2	chrX:153764217	chrX:153764217	C	T	G6PD rs1050828	rasburicase	G6PD	Toxicity/ADR	1A	Hemolysis,Methemoglobinemia,Protein Deficiency	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA10176	Urate oxidase,"Uricase","rasburicase"	Elitek,"Elitek","Fasturtec"	.	GenBank:X61766,"Web Resource:http://en.wikipedia.org/wiki/Rasburicase","UniProtKB:Q00511","National Drug Code Directory:0024-5150-10","DrugBank:DB00049","Chemical Abstracts Service:134774-45-1","Drugs Product Database (DPD):02248416","FDA Drug Label at DailyMed:0ae10bc4-6b65-402f-9db5-2d7753054922"	Yes	CPIC	Testing required	Testing required	25115783;27119769;19654083
1;2	chrX:153763492	chrX:153763492	T	C	G6PD rs1050829	rasburicase	G6PD	Toxicity/ADR	1A	Hemolysis,Methemoglobinemia,Protein Deficiency	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA10176	Urate oxidase,"Uricase","rasburicase"	Elitek,"Elitek","Fasturtec"	.	GenBank:X61766,"Web Resource:http://en.wikipedia.org/wiki/Rasburicase","UniProtKB:Q00511","National Drug Code Directory:0024-5150-10","DrugBank:DB00049","Chemical Abstracts Service:134774-45-1","Drugs Product Database (DPD):02248416","FDA Drug Label at DailyMed:0ae10bc4-6b65-402f-9db5-2d7753054922"	Yes	CPIC	Testing required	Testing required	25115783;27119769;19654083
1;2	chrX:153762634	chrX:153762634	G	A	G6PD rs5030868	rasburicase	G6PD	Toxicity/ADR	1A	Hemolysis,Methemoglobinemia,Protein Deficiency	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA10176	Urate oxidase,"Uricase","rasburicase"	Elitek,"Elitek","Fasturtec"	.	GenBank:X61766,"Web Resource:http://en.wikipedia.org/wiki/Rasburicase","UniProtKB:Q00511","National Drug Code Directory:0024-5150-10","DrugBank:DB00049","Chemical Abstracts Service:134774-45-1","Drugs Product Database (DPD):02248416","FDA Drug Label at DailyMed:0ae10bc4-6b65-402f-9db5-2d7753054922"	Yes	CPIC	Testing required	Testing required	25115783;27119769;19654083
1;2	chr10:96741053	chr10:96741053	A	C	CYP2C9*3	celecoxib	CYP2C9	Dosage	2A	.	PA126	CYP2C9	[GRCh37]chr10:96741053	98	11	4	0	Yes	XP_005269632.1:p.Ile359Leu, rs61212474, XP_005269632.1:p.Ile359=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NM_000771.3:c.1075A=, NP_000762.2:p.Ile359=, [GRCh37]chr10:96741053, rs1057910, rs3198471, NC_000010.11:g.94981296A=, NC_000010.10:g.96741053A>C, XM_005269575.1:c.1075A>C, [GRCh38]chr10:94981296, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, NG_008385.1:g.47639A>C, rs17847042, NP_000762.2:p.I359L, NC_000010.10:g.96741053A=, NM_000771.3:c.1075A>C	PA166153959	CYP2C9	PA166122826;PA166104843;PA166153432;PA166104922;PA166160007;PA166163422;PA166104860;PA166105222;PA166104917;PA166104776;PA166127647;PA166127732;PA166160153	Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for celecoxib and CYP2C9;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for flurbiprofen and CYP2C9;Annotation of FDA Label for lesinurad and CYP2C9;Annotation of FDA Label for marinol and CYP2C9;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for piroxicam and CYP2C9;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1;Annotation of HCSC Label for celecoxib and CYP2C9;Annotation of HCSC Label for warfarin and CYP2C9,VKORC1;Annotation of PMDA Label for celecoxib and CYP2C9	PA448871	Celocoxib,"celecoxib"	Celebra,"Celebrex","Onsenal"	.	Web Resource:http://en.wikipedia.org/wiki/Celecoxib,"National Drug Code Directory:0025-1515-01","DrugBank:DB00482","PDB:CEL","Chemical Abstracts Service:169590-42-5","ChEBI:3520","KEGG Compound:C07589","KEGG Drug:D00567","PubChem Compound:2662","PubChem Substance:205043","PubChem Substance:46505596","Drugs Product Database (DPD):02239941","BindingDB:11639","ChemSpider:2562","HET:CEL","Therapeutic Targets Database:DAP000737","FDA Drug Label at DailyMed:8d52185d-421f-4e34-8db7-f7676db2a226","ClinicalTrials.gov:NCT01705106"	No	.	Actionable PGx	Actionable PGx	27864660;16513453
1;2	chr19:45412079	chr19:45412079	C	T	APOE E2	pravastatin	APOE	Efficacy	3	.	.	.	.	.	.	.	.	.	.	.	APOE	PA166104866	Annotation of FDA Label for pravastatin and APOE	PA451089	Pravastatin Sodium,"Pravastatina [Spanish]","Pravastatine [French]","Pravastatinum [Latin]"	Compactin,"Elisor","Lipostat","Mevalotin","Mevastatin","Mevinolin","Oliprevin","Pravachol","Pravaselect","Selectin","Selipran","Vasten"	.	Web Resource:http://en.wikipedia.org/wiki/Pravastatin,"National Drug Code Directory:0003-5154-05","DrugBank:DB00175","KEGG Compound:C01844","PubChem Compound:54687","PubChem Substance:192211","PubChem Substance:46504851","Drugs Product Database (DPD):02247008","BindingDB:20688","ChemSpider:49398","Therapeutic Targets Database:DAP000550","FDA Drug Label at DailyMed:897ad8b7-921d-eb02-a61c-3419e662a2da","ClinicalTrials.gov:NCT01075555","ClinicalTrials.gov:NCT01788254"	No	.	Informative PGx	Informative PGx	16869455;18388879
1;2	chr12:21331549	chr12:21331549	T	C	SLCO1B1 rs4149056	pravastatin	SLCO1B1	Metabolism/PK	2A	.	PA134865839	SLCO1B1	[GRCh37]chr12:21331549	113	23	5	0	Yes	[GRCh38]chr12:21178615, NC_000012.12:g.21178615T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, NC_000012.11:g.21331549T>C, rs4149056, rs52816141, [GRCh37]chr12:21331549, NP_006437.3:p.V174A, rs60037639, NG_011745.1:g.52422T>C	PA166154579	SLCO1B1	PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	PA451089	Pravastatin Sodium,"Pravastatina [Spanish]","Pravastatine [French]","Pravastatinum [Latin]"	Compactin,"Elisor","Lipostat","Mevalotin","Mevastatin","Mevinolin","Oliprevin","Pravachol","Pravaselect","Selectin","Selipran","Vasten"	.	Web Resource:http://en.wikipedia.org/wiki/Pravastatin,"National Drug Code Directory:0003-5154-05","DrugBank:DB00175","KEGG Compound:C01844","PubChem Compound:54687","PubChem Substance:192211","PubChem Substance:46504851","Drugs Product Database (DPD):02247008","BindingDB:20688","ChemSpider:49398","Therapeutic Targets Database:DAP000550","FDA Drug Label at DailyMed:897ad8b7-921d-eb02-a61c-3419e662a2da","ClinicalTrials.gov:NCT01075555","ClinicalTrials.gov:NCT01788254"	No	.	Informative PGx	Informative PGx	17439540
1;2	chr10:96540410	chr10:96540410	G	A	CYP2C19*3	amitriptyline	CYP2C19	Efficacy,Toxicity/ADR	1A	.	.	.	.	.	.	.	.	.	.	.	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	PA448385	Amitriprolidine,"Amitriptylin","Amitriptyline HCL","Amitriptyline Hydrochloride","Amitryptiline","Amitryptyline","Amytriptiline"	Adepress,"Adepril","Amitid","Amitril","Damilan","Damilen","Elanil","Elavil","Endep","Flavyl","Hexathane","Horizon","Lantron","Laroxil","Laroxyl","Lentizol","Proheptadiene","Redomex","Saroten","Sarotex","Seroten","Sylvemid","Triptanol","Triptilin","Triptisol","Tryptanol","Tryptizol","dAmitriptyline"	Apo Peram Tab 2-25 (Amitriptyline Hydrochloride + Perphenazine),"Apo Peram Tab 3-15 (Amitriptyline Hydrochloride + Perphenazine)","Elavil Plus Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon 2 10 (Amitriptyline Hydrochloride + Perphenazine)","Etrafon D Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon F Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon a Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 2/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 3/15 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 4/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Proavil Tab (Amitriptyline Hydrochloride + Perphenazine)","Triavil Tab (Amitriptyline Hydrochloride + Perphenazine)"	Web Resource:http://en.wikipedia.org/wiki/Amitriptyline,"National Drug Code Directory:53489-104-07","DrugBank:DB00321","ChEBI:2666","KEGG Compound:C06824","PubChem Compound:2160","PubChem Substance:46508798","PubChem Substance:9042","IUPHAR Ligand:200","Drugs Product Database (DPD):00654515","ChemSpider:2075","Therapeutic Targets Database:DNC001466","FDA Drug Label at DailyMed:9f85491f-71ec-4772-8307-8ff2e9257546"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	12172336;28296334;15590749
1;2	chr10:96541616	chr10:96541616	G	A	CYP2C19*2	amitriptyline	CYP2C19	Efficacy	1A	.	PA124	CYP2C19	[GRCh37]chr10:96541616	133	11	4	0	Yes	NP_000760.1:p.Pro227=, NM_000769.2:c.681G>A, rs116940633, [GRCh37]chr10:96541616, NG_008384.2:g.24154G>A, [GRCh38]chr10:94781859, rs17879456, rs60361278, NC_000010.11:g.94781859G>A, NP_000760.1:p.P227P, rs4244285, NC_000010.10:g.96541616G>A, NM_000769.1:c.681G>A	PA166154053	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	PA448385	Amitriprolidine,"Amitriptylin","Amitriptyline HCL","Amitriptyline Hydrochloride","Amitryptiline","Amitryptyline","Amytriptiline"	Adepress,"Adepril","Amitid","Amitril","Damilan","Damilen","Elanil","Elavil","Endep","Flavyl","Hexathane","Horizon","Lantron","Laroxil","Laroxyl","Lentizol","Proheptadiene","Redomex","Saroten","Sarotex","Seroten","Sylvemid","Triptanol","Triptilin","Triptisol","Tryptanol","Tryptizol","dAmitriptyline"	Apo Peram Tab 2-25 (Amitriptyline Hydrochloride + Perphenazine),"Apo Peram Tab 3-15 (Amitriptyline Hydrochloride + Perphenazine)","Elavil Plus Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon 2 10 (Amitriptyline Hydrochloride + Perphenazine)","Etrafon D Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon F Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon a Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 2/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 3/15 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 4/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Proavil Tab (Amitriptyline Hydrochloride + Perphenazine)","Triavil Tab (Amitriptyline Hydrochloride + Perphenazine)"	Web Resource:http://en.wikipedia.org/wiki/Amitriptyline,"National Drug Code Directory:53489-104-07","DrugBank:DB00321","ChEBI:2666","KEGG Compound:C06824","PubChem Compound:2160","PubChem Substance:46508798","PubChem Substance:9042","IUPHAR Ligand:200","Drugs Product Database (DPD):00654515","ChemSpider:2075","Therapeutic Targets Database:DNC001466","FDA Drug Label at DailyMed:9f85491f-71ec-4772-8307-8ff2e9257546"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	11531654;12012142
1;2	chr22:42526694	chr22:42526694	G	A	CYP2D6*10	amitriptyline	CYP2D6	Efficacy,Toxicity/ADR	1A	Depressive Disorder, Major,Mental Disorders,Mood Disorders	.	.	.	.	.	.	.	.	.	.	CYP2D6	PA166104899;PA166122966;PA166119827;PA166123414;PA166129447;PA166122967;PA166104930;PA166104915;PA166122487;PA166122947;PA166123410;PA166115435;PA166123408;PA166104856;PA166127662;PA166104839;PA166161219;PA166104827;PA166160054;PA166177479;PA166104813;PA166104787;PA166104852;PA166104875;PA166104815;PA166104916;PA166122971;PA166104862;PA166177483;PA166169882;PA166104886;PA166105113;PA166104820;PA166105010;PA166123487;PA166105012;PA166122972;PA166153432;PA166104788;PA166104835;PA166104854;PA166177509;PA166104869;PA166170929;PA166104887;PA166104879;PA166104836;PA166177514;PA166104868;PA166105028;PA166104880;PA166104888;PA166105211;PA166160052;PA166104864;PA166104893;PA166104870;PA166104837;PA166104798;PA166104812;PA166104811;PA166105232;PA166104793;PA166170935;PA166160672;PA166104822;PA166104829;PA166104805;PA166104830;PA166104806;PA166104799;PA166104857;PA166177521;PA166170052;PA166104847;PA166122607;PA166127628;PA166127631;PA166127633;PA166127646;PA166127654;PA166127659;PA166127673;PA166127675;PA166127691;PA166127697;PA166127704;PA166127708;PA166127718;PA166127719;PA166127721;PA166127731;PA166123528;PA166160226;PA166160709;PA166160669;PA166160712;PA166123541;PA166160845;PA166160850;PA166123549	Annotation of EMA Label for aripiprazole and CYP2D6,CYP3A4;Annotation of EMA Label for darifenacin and CYP2D6;Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6;Annotation of EMA Label for dronedarone and CYP2D6,CYP3A4;Annotation of EMA Label for eliglustat and CYP2D6;Annotation of EMA Label for fesoterodine and CYP2D6;Annotation of EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR;Annotation of EMA Label for olanzapine and CYP1A2,CYP2D6;Annotation of EMA Label for propranolol and CYP2D6;Annotation of EMA Label for ranolazine and CYP2D6;Annotation of EMA Label for ritonavir and CYP2D6,CYP3A4;Annotation of EMA Label for timolol and CYP2D6;Annotation of EMA Label for vortioxetine and CYP2D6;Annotation of FDA Label for amitriptyline and CYP2D6;Annotation of FDA Label for arformoterol and CYP2D6,UGT1A1;Annotation of FDA Label for aripiprazole and CYP2D6;Annotation of FDA Label for aripiprazole lauroxil and CYP2D6;Annotation of FDA Label for atomoxetine and CYP2D6;Annotation of FDA Label for brexpiprazole and CYP2D6;Annotation of FDA Label for cariprazine and CYP2D6;Annotation of FDA Label for carvedilol and CYP2D6;Annotation of FDA Label for cevimeline and CYP2D6;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clomipramine and CYP2D6;Annotation of FDA Label for clozapine and CYP2D6;Annotation of FDA Label for codeine and CYP2D6;Annotation of FDA Label for darifenacin and CYP2D6;Annotation of FDA Label for desipramine and CYP2D6;Annotation of FDA Label for desvenlafaxine and CYP2D6;Annotation of FDA Label for deutetrabenazine and CYP2D6;Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6;Annotation of FDA Label for donepezil and CYP2D6;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for duloxetine and CYP2D6;Annotation of FDA Label for eliglustat and CYP2D6;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for fesoterodine and CYP2D6;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6;Annotation of FDA Label for fluoxetine and CYP2D6;Annotation of FDA Label for fluvoxamine and CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for galantamine and CYP2D6;Annotation of FDA Label for gefitinib and CYP2D6;Annotation of FDA Label for iloperidone and CYP2D6;Annotation of FDA Label for imipramine and CYP2D6;Annotation of FDA Label for metoprolol and CYP2D6;Annotation of FDA Label for mirabegron and CYP2D6;Annotation of FDA Label for modafinil and CYP2D6;Annotation of FDA Label for nebivolol and CYP2D6;Annotation of FDA Label for nefazodone and CYP2D6;Annotation of FDA Label for nortriptyline and CYP2D6;Annotation of FDA Label for ondansetron and CYP2D6;Annotation of FDA Label for palonosetron and CYP2D6;Annotation of FDA Label for paroxetine and CYP2D6;Annotation of FDA Label for perphenazine and CYP2D6;Annotation of FDA Label for pimozide and CYP2D6;Annotation of FDA Label for propafenone and CYP2D6;Annotation of FDA Label for propranolol and CYP2D6;Annotation of FDA Label for protriptyline and CYP2D6;Annotation of FDA Label for quinidine and CYP2D6;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for risperidone and CYP2D6;Annotation of FDA Label for rucaparib and CYP1A2,CYP2D6;Annotation of FDA Label for tamsulosin and CYP2D6;Annotation of FDA Label for terbinafine and CYP2D6;Annotation of FDA Label for tetrabenazine and CYP2D6;Annotation of FDA Label for thioridazine and CYP2D6;Annotation of FDA Label for tiotropium and CYP2D6;Annotation of FDA Label for tolterodine and CYP2D6;Annotation of FDA Label for tramadol and CYP2D6;Annotation of FDA Label for trimipramine and CYP2D6;Annotation of FDA Label for umeclidinium and CYP2D6;Annotation of FDA Label for valbenazine and CYP2D6;Annotation of FDA Label for venlafaxine and CYP2D6;Annotation of FDA Label for vortioxetine and CYP2D6;Annotation of HCSC Label for acetaminophen,tramadol and CYP2D6;Annotation of HCSC Label for aripiprazole and CYP2D6;Annotation of HCSC Label for atomoxetine and CYP2D6;Annotation of HCSC Label for carvedilol and CYP2D6;Annotation of HCSC Label for codeine and CYP2D6;Annotation of HCSC Label for darifenacin and CYP2D6;Annotation of HCSC Label for fesoterodine and CYP2D6;Annotation of HCSC Label for galantamine and CYP2D6;Annotation of HCSC Label for metoprolol and CYP2D6;Annotation of HCSC Label for nortriptyline and CYP2D6;Annotation of HCSC Label for propafenone and CYP2D6;Annotation of HCSC Label for risperidone and CYP2D6;Annotation of HCSC Label for tamoxifen and CYP2D6,ESR1,ESR2;Annotation of HCSC Label for tetrabenazine and CYP2D6;Annotation of HCSC Label for tolterodine and CYP2D6;Annotation of HCSC Label for vortioxetine and CYP2D6;Annotation of PMDA Label for atomoxetine and CYP2D6;Annotation of PMDA Label for codeine and CYP2D6;Annotation of PMDA Label for eliglustat and CYP2D6;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for fesoterodine and CYP2D6;Annotation of PMDA Label for gefitinib and CYP2D6,EGFR;Annotation of PMDA Label for perphenazine and CYP2D6;Annotation of PMDA Label for tetrabenazine and CYP2D6;Annotation of PMDA Label for tolterodine and CYP2D6	PA448385	Amitriprolidine,"Amitriptylin","Amitriptyline HCL","Amitriptyline Hydrochloride","Amitryptiline","Amitryptyline","Amytriptiline"	Adepress,"Adepril","Amitid","Amitril","Damilan","Damilen","Elanil","Elavil","Endep","Flavyl","Hexathane","Horizon","Lantron","Laroxil","Laroxyl","Lentizol","Proheptadiene","Redomex","Saroten","Sarotex","Seroten","Sylvemid","Triptanol","Triptilin","Triptisol","Tryptanol","Tryptizol","dAmitriptyline"	Apo Peram Tab 2-25 (Amitriptyline Hydrochloride + Perphenazine),"Apo Peram Tab 3-15 (Amitriptyline Hydrochloride + Perphenazine)","Elavil Plus Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon 2 10 (Amitriptyline Hydrochloride + Perphenazine)","Etrafon D Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon F Tab (Amitriptyline Hydrochloride + Perphenazine)","Etrafon a Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 2/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 3/15 Tab (Amitriptyline Hydrochloride + Perphenazine)","Pms-Levazine 4/25 Tab (Amitriptyline Hydrochloride + Perphenazine)","Proavil Tab (Amitriptyline Hydrochloride + Perphenazine)","Triavil Tab (Amitriptyline Hydrochloride + Perphenazine)"	Web Resource:http://en.wikipedia.org/wiki/Amitriptyline,"National Drug Code Directory:53489-104-07","DrugBank:DB00321","ChEBI:2666","KEGG Compound:C06824","PubChem Compound:2160","PubChem Substance:46508798","PubChem Substance:9042","IUPHAR Ligand:200","Drugs Product Database (DPD):00654515","ChemSpider:2075","Therapeutic Targets Database:DNC001466","FDA Drug Label at DailyMed:9f85491f-71ec-4772-8307-8ff2e9257546"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	12172336;28296334
1;2	chr11:113270828	chr11:113270828	G	A	ANKK1 rs1800497	second generation antipsychotics	ANKK1	Toxicity/ADR	3	Schizophrenia	PA134872551,PA27478	ANKK1,DRD2	[GRCh37]chr11:113270828	40	11	3	0	No	rs117686243, [GRCh37]chr11:113270828, XP_011541038.1:p.Glu724Lys, NC_000011.9:g.113270828G>A, XM_011542736.1:c.2170G>A, XM_011542737.1:c.2140G>A, NG_012976.1:g.17316G>A, XP_011541040.1:p.Glu650Lys, NM_178510.1:c.2137G>A, rs4134623, rs59538675, XP_011541039.1:p.Glu714Lys, rs1800497, NC_000011.10:g.113400106G>A, NP_848605.1:p.Glu713Lys, XM_011542738.1:c.1948G>A, NP_848605.1:p.E713K, rs4245144	PA166154339	.	.	.	PA151186253	.	.	.	.	No	.	.	.	23559402;18926547;25740917
1;2	chrX:153764217	chrX:153764217	C	T	G6PD rs1050828	chloroquine	G6PD	Toxicity/ADR	3	Anemia, Hemolytic	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA448948	Chloraquine,"Chlorochine","Chloroquina","Chloroquine Phosphate","Chloroquinium","Chlorquin","Clorochina","Hydroxychloroquine Sulfate"	3377 RP opalate,"Amokin","Aralen","Aralen HCl","Arechin","Arthrochin","Artrichin","Avlochlor","Avloclor","Bemaco","Bemaphate","Bemasulph","Benaquin","Bipiquin","Capquin","Chemochin","Chingamin","Chlorochin","Cidanchin","Cocartrit","Dawaquin","Delagil","Dichinalex","Elestol","Gontochin","Heliopar","Imagon","Iroquine","Klorokin","Lapaquin","Malaquin","Malaren","Malarex","Mesylith","Neochin","Nivachine","Nivaquine","Nivaquine B","Pfizerquine","Plaquenil","Quinachlor","Quinagamin","Quinagamine","Quinercyl","Quingamine","Quinilon","Quinoscan","Resochen","Resochin","Resoquina","Resoquine","Reumachlor","Reumaquin","Roquine","Sanoquin","Silbesan","Siragan","Solprina","Sopaquin","Tanakan","Tresochin","Trochin"	.	Web Resource:http://en.wikipedia.org/wiki/Chloroquine,"National Drug Code Directory:0024-0084-01","DrugBank:DB00608","PDB:CLQ","ChEBI:3638","KEGG Compound:C07625","KEGG Drug:D02366","PubChem Compound:2719","PubChem Substance:46506925","PubChem Substance:9827","Drugs Product Database (DPD):00021261","BindingDB:22985","ChemSpider:2618","HET:CLQ","Therapeutic Targets Database:DAP001357","FDA Drug Label at DailyMed:b48476e0-9f63-483e-89fe-1af123665951","ClinicalTrials.gov:NCT01218932"	No	.	Actionable PGx	Actionable PGx	15655011
1;2	chrX:153763492	chrX:153763492	T	C	G6PD rs1050829	chloroquine	G6PD	Toxicity/ADR	3	Anemia, Hemolytic	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA448948	Chloraquine,"Chlorochine","Chloroquina","Chloroquine Phosphate","Chloroquinium","Chlorquin","Clorochina","Hydroxychloroquine Sulfate"	3377 RP opalate,"Amokin","Aralen","Aralen HCl","Arechin","Arthrochin","Artrichin","Avlochlor","Avloclor","Bemaco","Bemaphate","Bemasulph","Benaquin","Bipiquin","Capquin","Chemochin","Chingamin","Chlorochin","Cidanchin","Cocartrit","Dawaquin","Delagil","Dichinalex","Elestol","Gontochin","Heliopar","Imagon","Iroquine","Klorokin","Lapaquin","Malaquin","Malaren","Malarex","Mesylith","Neochin","Nivachine","Nivaquine","Nivaquine B","Pfizerquine","Plaquenil","Quinachlor","Quinagamin","Quinagamine","Quinercyl","Quingamine","Quinilon","Quinoscan","Resochen","Resochin","Resoquina","Resoquine","Reumachlor","Reumaquin","Roquine","Sanoquin","Silbesan","Siragan","Solprina","Sopaquin","Tanakan","Tresochin","Trochin"	.	Web Resource:http://en.wikipedia.org/wiki/Chloroquine,"National Drug Code Directory:0024-0084-01","DrugBank:DB00608","PDB:CLQ","ChEBI:3638","KEGG Compound:C07625","KEGG Drug:D02366","PubChem Compound:2719","PubChem Substance:46506925","PubChem Substance:9827","Drugs Product Database (DPD):00021261","BindingDB:22985","ChemSpider:2618","HET:CLQ","Therapeutic Targets Database:DAP001357","FDA Drug Label at DailyMed:b48476e0-9f63-483e-89fe-1af123665951","ClinicalTrials.gov:NCT01218932"	No	.	Actionable PGx	Actionable PGx	15655011
1;2	chrX:153762634	chrX:153762634	G	A	G6PD rs5030868	chloroquine	G6PD	Toxicity/ADR	3	Anemia, Hemolytic	.	.	.	.	.	.	.	.	.	.	G6PD	PA166120370;PA166104823;PA166121327;PA166104894;PA166104786;PA166114910;PA166114913;PA166104845;PA166104895;PA166104881;PA166105147;PA166105148;PA166105178;PA166114926;PA166104878;PA166105195;PA166104897;PA166104891;PA166104903;PA166104885;PA166104900;PA166104876;PA166104906;PA166105232;PA166151881;PA166115362;PA166115363;PA166104902;PA166104874;PA166104892;PA166170937;PA166127649;PA166127657;PA166127717;PA166127677;PA166127678;PA166127729;PA166127694;PA166127696;PA166127702;PA166127705;PA166127707;PA166129528;PA166127714;PA166127715;PA166127716;PA166160683;PA166160718;PA166160854;PA166160719;PA166123548;PA166160847;PA166160848;PA166160849	Annotation of EMA Label for glimepiride and G6PD;Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD;Annotation of EMA Label for pegloticase and G6PD;Annotation of EMA Label for rasburicase and G6PD;Annotation of FDA Label for chloroquine and G6PD;Annotation of FDA Label for chlorpropamide and G6PD;Annotation of FDA Label for dabrafenib and G6PD;Annotation of FDA Label for dapsone and G6PD;Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of FDA Label for glibenclamide and G6PD;Annotation of FDA Label for glimepiride and G6PD;Annotation of FDA Label for glipizide and G6PD;Annotation of FDA Label for lidocaine / prilocaine and G6PD;Annotation of FDA Label for mafenide and G6PD;Annotation of FDA Label for methylene blue and G6PD;Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of FDA Label for moviprep and G6PD;Annotation of FDA Label for nalidixic acid and G6PD;Annotation of FDA Label for nitrofurantoin and G6PD;Annotation of FDA Label for norfloxacin and G6PD;Annotation of FDA Label for pegloticase and G6PD;Annotation of FDA Label for primaquine and G6PD;Annotation of FDA Label for probenecid and G6PD;Annotation of FDA Label for quinine and CYP2D6,G6PD;Annotation of FDA Label for rasburicase and G6PD;Annotation of FDA Label for sodium nitrite and G6PD;Annotation of FDA Label for succimer and G6PD;Annotation of FDA Label for sulfadiazine and G6PD;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of FDA Label for trametinib and G6PD;Annotation of HCSC Label for chlorpropamide and G6PD;Annotation of HCSC Label for dapsone and G6PD;Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD;Annotation of HCSC Label for glibenclamide and G6PD;Annotation of HCSC Label for glimepiride and G6PD;Annotation of HCSC Label for moviprep and G6PD;Annotation of HCSC Label for nitrofurantoin and G6PD;Annotation of HCSC Label for norfloxacin and G6PD;Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD;Annotation of HCSC Label for quinine and G6PD;Annotation of HCSC Label for rasburicase and G6PD;Annotation of HCSC Label for sodium nitrite and G6PD;Annotation of HCSC Label for sulfadiazine and G6PD;Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of HCSC Label for sulfasalazine and G6PD;Annotation of PMDA Label for dapsone and G6PD;Annotation of PMDA Label for methylene blue and BLVRB,G6PD;Annotation of PMDA Label for moviprep and G6PD;Annotation of PMDA Label for nalidixic acid and G6PD;Annotation of PMDA Label for rasburicase and G6PD;Annotation of PMDA Label for sulfadiazine and G6PD;Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD;Annotation of PMDA Label for sulfasalazine and G6PD	PA448948	Chloraquine,"Chlorochine","Chloroquina","Chloroquine Phosphate","Chloroquinium","Chlorquin","Clorochina","Hydroxychloroquine Sulfate"	3377 RP opalate,"Amokin","Aralen","Aralen HCl","Arechin","Arthrochin","Artrichin","Avlochlor","Avloclor","Bemaco","Bemaphate","Bemasulph","Benaquin","Bipiquin","Capquin","Chemochin","Chingamin","Chlorochin","Cidanchin","Cocartrit","Dawaquin","Delagil","Dichinalex","Elestol","Gontochin","Heliopar","Imagon","Iroquine","Klorokin","Lapaquin","Malaquin","Malaren","Malarex","Mesylith","Neochin","Nivachine","Nivaquine","Nivaquine B","Pfizerquine","Plaquenil","Quinachlor","Quinagamin","Quinagamine","Quinercyl","Quingamine","Quinilon","Quinoscan","Resochen","Resochin","Resoquina","Resoquine","Reumachlor","Reumaquin","Roquine","Sanoquin","Silbesan","Siragan","Solprina","Sopaquin","Tanakan","Tresochin","Trochin"	.	Web Resource:http://en.wikipedia.org/wiki/Chloroquine,"National Drug Code Directory:0024-0084-01","DrugBank:DB00608","PDB:CLQ","ChEBI:3638","KEGG Compound:C07625","KEGG Drug:D02366","PubChem Compound:2719","PubChem Substance:46506925","PubChem Substance:9827","Drugs Product Database (DPD):00021261","BindingDB:22985","ChemSpider:2618","HET:CLQ","Therapeutic Targets Database:DAP001357","FDA Drug Label at DailyMed:b48476e0-9f63-483e-89fe-1af123665951","ClinicalTrials.gov:NCT01218932"	No	.	Actionable PGx	Actionable PGx	15655011
1;2	chr8:18080116	chr8:18080116	G	A	NAT1*14A	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18080116	chr8:18080116	G	A	NAT1*14B	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18080115	chr8:18080115	C	T	NAT1*15	isoniazid	NAT1	.	.	.	.	 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18079746	chr8:18079746	C	T	NAT1*17	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18079653	chr8:18079653	C	T	NAT1*19A	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18079653	chr8:18079653	C	T	NAT1*19B	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18079746	chr8:18079746	C	T	NAT1*19B	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18080308	chr8:18080308	A	T	NAT1*22	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
1;2	chr8:18257877	chr8:18257877	G	A	NAT2*12D	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257704	chr8:18257704	G	A	NAT2*14A	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257947	chr8:18257947	A	C	NAT2*17	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257703	chr8:18257703	C	T	NAT2*19	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5A	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5A	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5B	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5B	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5C	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5D	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5E	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*5E	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5F	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5F	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258272	chr8:18258272	C	T	NAT2*5F	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5G	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5G	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257795	chr8:18257795	C	T	NAT2*5G	isoniazid	NAT2	Toxicity/ADR	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18257795	4	1	1	0	Yes	XM_011544358.1:c.282C>T, rs59855457, NC_000008.10:g.18257795C>T, NG_012246.1:g.14041C>T, rs17858364, NC_000008.11:g.18400285C>T, NP_000006.2:p.Y94Y, NP_000006.2:p.Tyr94=, NM_000015.2:c.282C>T, [GRCh38]chr8:18400285, XP_011542660.1:p.Tyr94=, rs1041983, rs17845484, [GRCh37]chr8:18257795	PA166157549	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5H	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5H	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258372	chr8:18258372	T	-	NAT2*5H	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257854	chr8:18257854	T	C	NAT2*5I	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*5I	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257924	chr8:18257924	A	T	NAT2*5I	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*6A	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257795	chr8:18257795	C	T	NAT2*6A	isoniazid	NAT2	Toxicity/ADR	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18257795	4	1	1	0	Yes	XM_011544358.1:c.282C>T, rs59855457, NC_000008.10:g.18257795C>T, NG_012246.1:g.14041C>T, rs17858364, NC_000008.11:g.18400285C>T, NP_000006.2:p.Y94Y, NP_000006.2:p.Tyr94=, NM_000015.2:c.282C>T, [GRCh38]chr8:18400285, XP_011542660.1:p.Tyr94=, rs1041983, rs17845484, [GRCh37]chr8:18257795	PA166157549	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*6B	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*6C	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257795	chr8:18257795	C	T	NAT2*6C	isoniazid	NAT2	Toxicity/ADR	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18257795	4	1	1	0	Yes	XM_011544358.1:c.282C>T, rs59855457, NC_000008.10:g.18257795C>T, NG_012246.1:g.14041C>T, rs17858364, NC_000008.11:g.18400285C>T, NP_000006.2:p.Y94Y, NP_000006.2:p.Tyr94=, NM_000015.2:c.282C>T, [GRCh38]chr8:18400285, XP_011542660.1:p.Tyr94=, rs1041983, rs17845484, [GRCh37]chr8:18257795	PA166157549	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257624	chr8:18257624	T	C	NAT2*6D	isoniazid	NAT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*6D	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257795	chr8:18257795	C	T	NAT2*6D	isoniazid	NAT2	Toxicity/ADR	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18257795	4	1	1	0	Yes	XM_011544358.1:c.282C>T, rs59855457, NC_000008.10:g.18257795C>T, NG_012246.1:g.14041C>T, rs17858364, NC_000008.11:g.18400285C>T, NP_000006.2:p.Y94Y, NP_000006.2:p.Tyr94=, NM_000015.2:c.282C>T, [GRCh38]chr8:18400285, XP_011542660.1:p.Tyr94=, rs1041983, rs17845484, [GRCh37]chr8:18257795	PA166157549	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257994	chr8:18257994	C	T	NAT2*6E	isoniazid	NAT2	Toxicity/ADR	3	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258103	chr8:18258103	G	A	NAT2*6E	isoniazid	NAT2	Toxicity/ADR,Metabolism/PK	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258103	9	1	1	0	Yes	XM_011544358.1:c.590G>A, NP_000006.2:p.Arg197Gln, NP_000006.2:p.R197Q, NG_012246.1:g.14349G>A, rs1799930, rs17856496, rs61467963, NC_000008.10:g.18258103G>A, rs4646269, NC_000008.11:g.18400593G>A, NM_000015.2:c.590G>A, XP_011542660.1:p.Arg197Gln, [GRCh38]chr8:18400593, rs17517027, rs60190029, [GRCh37]chr8:18258103	PA166157564	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18257795	chr8:18257795	C	T	NAT2*7B	isoniazid	NAT2	Toxicity/ADR	2A	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18257795	4	1	1	0	Yes	XM_011544358.1:c.282C>T, rs59855457, NC_000008.10:g.18257795C>T, NG_012246.1:g.14041C>T, rs17858364, NC_000008.11:g.18400285C>T, NP_000006.2:p.Y94Y, NP_000006.2:p.Tyr94=, NM_000015.2:c.282C>T, [GRCh38]chr8:18400285, XP_011542660.1:p.Tyr94=, rs1041983, rs17845484, [GRCh37]chr8:18257795	PA166157549	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr8:18258370	chr8:18258370	G	A	NAT2*7B	isoniazid	NAT2	Toxicity/ADR	3	Tuberculosis	PA18	NAT2	[GRCh37]chr8:18258370	10	2	0	0	Yes	NP_000006.2:p.G286E, XP_011542660.1:p.Gly286Glu, NC_000008.11:g.18400860G>A, NG_012246.1:g.14616G>A, rs4646270, rs58803786, [GRCh37]chr8:18258370, rs17693862, XM_011544358.1:c.857G>A, NP_000006.2:p.Gly286Glu, [GRCh38]chr8:18400860, NC_000008.10:g.18258370G>A, rs1799931, rs52802193, NM_000015.2:c.857G>A	PA166157565	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
1;2	chr10:96540410	chr10:96540410	G	A	CYP2C19*3	voriconazole	CYP2C19	Metabolism/PK	1A	Mycoses	.	.	.	.	.	.	.	.	.	.	CYP2C19	PA166123421;PA166123387;PA166104841;PA166120286;PA166105321;PA166114382;PA166122826;PA166153492;PA166104832;PA166104852;PA166104884;PA166104777;PA166104863;PA166104784;PA166104820;PA166104814;PA166105012;PA166104816;PA166153432;PA166177509;PA166160049;PA166104898;PA166104808;PA166104921;PA166104901;PA166104860;PA166104917;PA166104848;PA166104851;PA166104818;PA166159707;PA166160289;PA166127650;PA166127653;PA166127661;PA166127670;PA166127698;PA166127706;PA166127730;PA166161536;PA166123535;PA166160669;PA166160720;PA166160846;PA166160856	Annotation of EMA Label for atazanavir and CYP2C19;Annotation of EMA Label for axitinib and CYP2C19,UGT1A1;Annotation of EMA Label for clopidogrel and CYP2C19;Annotation of EMA Label for esomeprazole and CYP2C19;Annotation of EMA Label for prasugrel and CYP2C19;Annotation of EMA Label for ticagrelor and CYP2C19;Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4;Annotation of FDA Label for brivaracetam and CYP2C19;Annotation of FDA Label for carisoprodol and CYP2C19;Annotation of FDA Label for citalopram and CYP2C19,CYP2D6;Annotation of FDA Label for clobazam and CYP2C19;Annotation of FDA Label for clopidogrel and CYP2C19;Annotation of FDA Label for dexlansoprazole and CYP2C19;Annotation of FDA Label for diazepam and CYP2C19;Annotation of FDA Label for doxepin and CYP2C19,CYP2D6;Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19;Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of FDA Label for esomeprazole and CYP2C19;Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6;Annotation of FDA Label for formoterol and CYP2C19,CYP2D6;Annotation of FDA Label for lacosamide and CYP2C19;Annotation of FDA Label for lansoprazole and CYP2C19;Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A;Annotation of FDA Label for omeprazole and CYP2C19;Annotation of FDA Label for pantoprazole and CYP2C19;Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B;Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5;Annotation of FDA Label for rabeprazole and CYP2C19;Annotation of FDA Label for ticagrelor and CYP2C19;Annotation of FDA Label for voriconazole and CYP2C19;Annotation of HCSC Label for atazanavir and CYP2C19;Annotation of HCSC Label for brivaracetam and CYP2C19;Annotation of HCSC Label for citalopram and CYP2C19;Annotation of HCSC Label for clopidogrel and CYP2C19;Annotation of HCSC Label for dexlansoprazole and CYP2C19;Annotation of HCSC Label for esomeprazole and CYP2C19;Annotation of HCSC Label for omeprazole and CYP2C19;Annotation of HCSC Label for rabeprazole and CYP2C19;Annotation of HCSC Label for voriconazole and CYP2C19;Annotation of PMDA Label for atazanavir and CYP2C19;Annotation of PMDA Label for clopidogrel and CYP2C19;Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6;Annotation of PMDA Label for omeprazole and CYP2C19;Annotation of PMDA Label for rabeprazole and CYP2C19;Annotation of PMDA Label for voriconazole and CYP2C19	PA10233	VCZ,"voriconazole"	Vfend	.	Web Resource:http://en.wikipedia.org/wiki/Voriconazole,"National Drug Code Directory:0049-3190-28","DrugBank:DB00582","Chemical Abstracts Service:137234-62-9","ChEBI:10023","KEGG Compound:C07622","KEGG Drug:D00578","PubChem Compound:71616","PubChem Substance:213886","PubChem Substance:46506421","Drugs Product Database (DPD):02256460","ChemSpider:64684","Therapeutic Targets Database:DAP001271","FDA Drug Label at DailyMed:ce3ef5cf-3087-4d92-9d94-9eb8287228db","ClinicalTrials.gov:NCT00371605","ClinicalTrials.gov:NCT00673348","ClinicalTrials.gov:NCT01104376","ClinicalTrials.gov:NCT01321372"	Yes	CPIC,"DPWG"	Actionable PGx	Actionable PGx	24510446;19299322
1;2	chr10:96541616	chr10:96541616	G	A	CYP2C19*2	voriconazole	CYP2C19	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28247033;28604474
1;2	chrX:153764217	chrX:153764217	C	T	G6PD rs1050828	dapsone	G6PD	Toxicity/ADR	1B	Malaria	PA28469,PA29777	G6PD,IKBKG	[GRCh37]chrX:153764217	12	3	1	0	Yes	NG_009015.2:g.16571G>A, XP_005274714.1:p.Val98Met, NC_000023.11:g.154536002C>T, XM_005277833.1:c.292G>A, XP_005277890.1:p.Val98Met, rs3191188, NM_001042351.2:c.202G>A, XM_005274657.2:c.292G>A, XP_011529434.1:p.Val98Met, NC_000023.10:g.153764217C>T, XM_011531132.1:c.292G>A, XM_005274657.1:c.292G>A, XM_005274658.2:c.202G>A, NP_000393.4:p.V98M, NP_001035810.1:p.Val68Met, [GRCh37]chrX:153764217, XP_005277891.1:p.Val68Met, NM_000402.4:c.292G>A, [GRCh38]chrX:154536002, XM_005274658.1:c.202G>A, rs1894404, XM_005277834.1:c.202G>A, NW_003871103.3:g.1969981C>T, NP_000393.4:p.Val98Met, XP_005274715.1:p.Val68Met, rs2230034, rs1050828	PA166157859	.	.	.	.	.	.	.	.	.	.	.	.	19112496;24372186
1;2	chrX:153763492	chrX:153763492	T	C	G6PD rs1050829	dapsone	G6PD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19112496;24372186
1;2	chrX:153762634	chrX:153762634	G	A	G6PD rs5030868	dapsone	G6PD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19112496;24372186
0;1	chr19:45411941	chr19:45411941	T	C	APOE E2	pravastatin	APOE	Efficacy	3	.	.	.	.	.	.	.	.	.	.	.	APOE	PA166104866	Annotation of FDA Label for pravastatin and APOE	PA451089	Pravastatin Sodium,"Pravastatina [Spanish]","Pravastatine [French]","Pravastatinum [Latin]"	Compactin,"Elisor","Lipostat","Mevalotin","Mevastatin","Mevinolin","Oliprevin","Pravachol","Pravaselect","Selectin","Selipran","Vasten"	.	Web Resource:http://en.wikipedia.org/wiki/Pravastatin,"National Drug Code Directory:0003-5154-05","DrugBank:DB00175","KEGG Compound:C01844","PubChem Compound:54687","PubChem Substance:192211","PubChem Substance:46504851","Drugs Product Database (DPD):02247008","BindingDB:20688","ChemSpider:49398","Therapeutic Targets Database:DAP000550","FDA Drug Label at DailyMed:897ad8b7-921d-eb02-a61c-3419e662a2da","ClinicalTrials.gov:NCT01075555","ClinicalTrials.gov:NCT01788254"	No	.	Informative PGx	Informative PGx	16869455;18388879
0;1	chr8:18080644	chr8:18080644	A	T	NAT1*14A	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
0;1	chr8:18080651	chr8:18080651	A	C	NAT1*14A	isoniazid	NAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28888949;24467436;15855489
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*12D	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5B	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5C	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5F	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5G	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5H	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*5I	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr8:18258316	chr8:18258316	G	A	NAT2*6C	isoniazid	NAT2	Toxicity/ADR	2A	Drug Toxicity,Hepatitis, Toxic,Toxic liver disease,Tuberculosis	.	.	.	.	.	.	.	.	.	.	NAT2	PA166104828;PA166104850;PA166104874;PA166104892;PA166161087	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2;Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2;Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2;Annotation of FDA Label for sulfasalazine and G6PD,NAT2;Annotation of PMDA Label for isoniazid and NAT2	.	.	.	.	.	.	.	.	.	9429236;24888881;19761367
0;1	chr7:99270539	chr7:99270539	C	T	CYP3A5*3	tacrolimus	CYP3A5	Dosage,Metabolism/PK	1A	heart transplantation,hemopoietic stem cell transplant,Kidney Transplantation,lung transplantation	PA27114,PA131,PA134962723	CYP3A,CYP3A5,ZSCAN25	[GRCh37]chr7:99270539	345	34	6	0	Yes	XM_005250170.1:c.-357-1G>A, XM_011515845.1:c.-463-1A>G, rs11266830, [GRCh37]chr7:99270539, NR_033810.1:n.689-1G>A, XM_005250169.1:c.189-237G>A, rs776746, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, XM_005250171.1:c.-253-1G>A, rs386613022, NC_000007.13:g.99270539C>T, XR_927402.1:n.1466+48736T>C, [GRCh38]chr7:99672916, XM_006715859.2:c.219-237A>G, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_011515846.1:c.-331-237A>G, XM_011515844.1:c.-229-237A>G, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NR_033808.1:n.689-1G>A, NC_000007.14:g.99672916T>C, rs10361242, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NR_033809.1:n.581-237G>A, NR_033811.1:n.321-1G>A, XM_011515843.1:c.-254A>G, XM_011515847.1:c.-571-1A>G, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, rs58244770, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NR_033812.1:n.321-1G>A, XM_005250172.1:c.-254G>A, XR_927383.1:n.344-237A>G	PA166157267	.	.	.	PA451578	FK-506,"FK5","FK506","K506","Tacarolimus","tacrolimus","tacrolimus hydrate"	Fujimycin,"LCP-Tacro","Prograf","Protopic"	.	Web Resource:http://en.wikipedia.org/wiki/Tacrolimus,"National Drug Code Directory:0469-0607-73","DrugBank:DB00864","PDB:FK5","ChEBI:61049","KEGG Compound:C01375","PubChem Compound:445643","PubChem Substance:46506004","Drugs Product Database (DPD):02243144","HET:FK5","Therapeutic Targets Database:DAP000162","FDA Drug Label at DailyMed:7f667de1-9dfa-4bd6-8ba0-15ee2d78873b","ClinicalTrials.gov:NCT00337493","ClinicalTrials.gov:NCT00445744","ClinicalTrials.gov:NCT00552201","ClinicalTrials.gov:NCT00611351","ClinicalTrials.gov:NCT00975663","ClinicalTrials.gov:NCT01068067","ClinicalTrials.gov:NCT01207141","ClinicalTrials.gov:NCT01288521","ClinicalTrials.gov:NCT01388387","ClinicalTrials.gov:NCT01413685","ClinicalTrials.gov:NCT01435291","ClinicalTrials.gov:NCT01655563","ClinicalTrials.gov:NCT01760356"	Yes	CPIC,"DPWG"	.	.	24522145;25201288;28704257
